<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1313" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1313/" /><meta name="ncbi_pagename" content="Calpainopathy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Calpainopathy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Calpainopathy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/08/03" /><meta name="citation_author" content="Corrado Angelini" /><meta name="citation_author" content="Marina Fanin" /><meta name="citation_pmid" content="20301490" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1313/" /><meta name="citation_keywords" content="Limb-Girdle Muscular Dystrophy Type 2A" /><meta name="citation_keywords" content="LGMD2A" /><meta name="citation_keywords" content="HyperCKemia" /><meta name="citation_keywords" content="Scapulohumeral Limb-Girdle Muscular Dystrophy (Erb LGMD)" /><meta name="citation_keywords" content="Pelvifemoral Limb-Girdle Muscular Dystrophy (Leyden-Möbius LGMD)" /><meta name="citation_keywords" content="Calpain-3" /><meta name="citation_keywords" content="CAPN3" /><meta name="citation_keywords" content="Calpainopathy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Calpainopathy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Corrado Angelini" /><meta name="DC.Contributor" content="Marina Fanin" /><meta name="DC.Date" content="2017/08/03" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1313/" /><meta name="description" content="Calpainopathy is characterized by symmetric and progressive weakness of proximal limb-girdle muscles. The age at onset of muscle weakness ranges from two to 40 years. The phenotype shows intra- and interfamilial variability ranging from severe to mild." /><meta name="og:title" content="Calpainopathy" /><meta name="og:type" content="book" /><meta name="og:description" content="Calpainopathy is characterized by symmetric and progressive weakness of proximal limb-girdle muscles. The age at onset of muscle weakness ranges from two to 40 years. The phenotype shows intra- and interfamilial variability ranging from severe to mild." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1313/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/lgmd2a/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1313/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8AEE42E042835100000000005D0022.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1313_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1313_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/caffey/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/campo-dysp/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1313_"><span class="title" itemprop="name">Calpainopathy</span></h1><p class="contrib-group"><span itemprop="author">Corrado Angelini</span>, MD and <span itemprop="author">Marina Fanin</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1313_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1313_ai__"><div class="contrib half_rhythm"><span itemprop="author">Corrado Angelini</span>, MD<div class="affiliation small">Department of Neurosciences<br />University of Padova<br />Padova, Italy</div><div class="affiliation small">IRCCS San Camillo Hospital<br />Venice, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.dpinu@inilegna.odarroc" class="oemail">ti.dpinu@inilegna.odarroc</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Marina Fanin</span>, PhD<div class="affiliation small">Department of Neurosciences<br />University of Padova<br />Padova, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.dpinu@ninaf.aniram" class="oemail">ti.dpinu@ninaf.aniram</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">May 10, 2005</span>; Last Update: <span itemprop="dateModified">August 3, 2017</span>.</p><p><em>Estimated reading time: 39 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="lgmd2a.Summary" itemprop="description"><h2 id="_lgmd2a_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Calpainopathy is characterized by symmetric and progressive weakness of proximal limb-girdle muscles. The age at onset of muscle weakness ranges from two to 40 years. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> shows intra- and <a class="def" href="/books/n/gene/glossary/def-item/interfamilial-variability/">interfamilial variability</a> ranging from severe to mild.</p><p>Three <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> calpainopathy phenotypes have been identified based on the distribution of muscle weakness and age at onset:</p><ul><li class="half_rhythm"><div>Pelvifemoral limb-girdle muscular dystrophy (LGMD) (Leyden-M&#x000f6;bius LGMD) <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, the most frequently observed calpainopathy phenotype, in which muscle weakness is first evident in the pelvic girdle and later in the shoulder girdle, with onset that may occur as early as before age 12 years or as late as after age 30 years</div></li><li class="half_rhythm"><div>Scapulohumeral LGMD (Erb LGMD) <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, usually a milder phenotype with infrequent early onset, in which muscle weakness is first evident in the shoulder girdle and later in the pelvic girdle</div></li><li class="half_rhythm"><div>HyperCKemia, usually observed in children or young individuals, in which individuals are asymptomatic and have high serum creatine kinase (CK) concentrations</div></li></ul><p>The <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of calpainopathy shows a variability of clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, ranging from almost asymptomatic to wheelchair dependence after age 60 years in few cases with a generally milder phenotype than the recessive form.</p><p>Clinical findings of calpainopathy include the tendency to walk on tiptoe, difficulty in running, scapular winging, waddling gait, and slight hyperlordosis. Other findings include symmetric weakness of proximal more than distal muscles in the limbs, trunk, and periscapular area; laxity of the abdominal muscles; Achilles tendon shortening; scoliosis; and joint contractures. Affected individuals typically do not have cardiac involvement or intellectual disability.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of calpainopathy, which is suggested by clinical findings and elevated serum CK concentration, is established by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CAPN3</i> (encoding proteolytic enzyme calpain-3) or a dominantly acting <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> for the <i>CAPN3</i> 21-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (c.643_663del21) by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. If such testing is not available or not conclusive, muscle biopsy with protein immuno-analysis should be used for diagnostic confirmation.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Physical therapy and stretching exercises to promote mobility and prevent contractures; aids such as canes, walkers, orthotics, and wheelchairs to help maintain independence; surgery for foot deformities, scoliosis, and Achilles tendon contractures as needed; respiratory aids to treat chronic respiratory insufficiency in late stages of the disease.</p><p><i>Surveillance:</i> Monitoring of muscle strength, joint range of motion, respiratory function, and orthopedic complications.</p><p><i>Agents/circumstances to avoid:</i> Strenuous and excessive muscle exercise; obesity and excessive weight loss; physical trauma, bone fractures, and prolonged immobility.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Calpainopathy is typically inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Less commonly, calpainopathy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. In the autosomal recessive form, at conception each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. To date, all individuals diagnosed with autosomal dominant calpainopathy have inherited a pathogenic <i>CAPN3</i> variant from a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent. Testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known.</p></div></div><div id="lgmd2a.GeneReview_Scope"><h2 id="_lgmd2a_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="lgmd2a.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1313/table/lgmd2a.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__lgmd2a.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_lgmd2a.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">Calpainopathy: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_lgmd2a.Td_1_1_1_1" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Pelvifemoral limb-girdle muscular dystrophy (Leyden-M&#x000f6;bius LGMD)</div></li><li class="half_rhythm"><div>Scapulohumeral limb-girdle muscular dystrophy (Erb LGMD)</div></li><li class="half_rhythm"><div>HyperCKemia</div></li></ul></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#lgmd2a.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="lgmd2a.TF.d.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#lgmd2a.Differential_Diagnosis">Differential Diagnosis</a><i>.</i></p></div></dd></dl></div></div></div></div><div id="lgmd2a.Diagnosis"><h2 id="_lgmd2a_Diagnosis_">Diagnosis</h2><p>Calpainopathy is a form of limb-girdle muscular dystrophy (LGMD).</p><div id="lgmd2a.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Calpainopathy <b>should be suspected</b> in individuals with the following clinical findings and test results.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Proximal muscle weakness (pelvic and/or shoulder girdle) with early onset (age &#x0003c;12 years), adult onset, or late onset (age &#x0003e;30 years)</div></li><li class="half_rhythm"><div>Symmetric atrophy and wasting of proximal limb and trunk muscles; calf hypertrophy is rarely and sometimes only transiently present [<a class="bk_pop" href="#lgmd2a.REF.fardeau.1996.295">Fardeau et al 1996</a>].</div></li><li class="half_rhythm"><div>Scapular winging, scoliosis, Achilles tendon contracture, and other joint contractures (including hip, knee, elbow, finger, and spine)</div></li><li class="half_rhythm"><div>Waddling gait; tip-toe walking; difficulty in running, climbing stairs, lifting weights, and getting up from the floor or from a chair</div></li><li class="half_rhythm"><div>Sparing of facial, ocular, tongue, and neck muscles</div></li><li class="half_rhythm"><div>Elevated creatine kinase (CK) concentrations, especially in childhood or adolescence, with or without overt muscle symptoms</div></li><li class="half_rhythm"><div>Absence of cardiomyopathy and intellectual disability</div></li><li class="half_rhythm"><div>Back pain and myalgia; present in 50% of individuals with dominantly inherited calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>]</div></li></ul><p><b>Clinical testing</b></p><ul><li class="half_rhythm"><div><b>Serum creatine kinase (CK) concentration</b> is always elevated (5-80x normal) from early infancy on, particularly during the active stage of the disease. Serum CK concentration decreases with disease progression, as muscles become more and more atrophic [<a class="bk_pop" href="#lgmd2a.REF.urtasun.1998.1735">Urtasun et al 1998</a>]. In the dominant form of calpainopathy, some individuals presented normal CK levels [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>].</div></li><li class="half_rhythm"><div><b>Muscle imaging</b></div><ul><li class="half_rhythm"><div>CT reveals early and striking wasting of muscles predominantly from the posterior compartment of the thighs (but also hip adductors and quadriceps), which is also evident on clinical examination [<a class="bk_pop" href="#lgmd2a.REF.fardeau.1996.295">Fardeau et al 1996</a>, <a class="bk_pop" href="#lgmd2a.REF.urtasun.1998.1735">Urtasun et al 1998</a>], with sparing of the sartorius and gracilis muscles. The difference in distribution of muscle involvement between calpainopathy and other LGMDs (i.e., sarcoglycanopathies and dysferlinopathies) makes muscle imaging analysis an important element in clinical diagnosis [<a class="bk_pop" href="#lgmd2a.REF.ten_dam.2012.1716">ten Dam et al 2012</a>] (see <a href="#lgmd2a.Differential_Diagnosis">Differential Diagnosis</a>).</div></li><li class="half_rhythm"><div>MRI shows this selective muscle involvement and in some cases reveals edema-like changes on STIR sequences [<a class="bk_pop" href="#lgmd2a.REF.fischer.2005.538">Fischer et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.mercuri.2005.164">Mercuri et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.borsato.2006.17">Borsato et al 2006</a>, <a class="bk_pop" href="#lgmd2a.REF.degardin.2010.1219">Degardin et al 2010</a>, <a class="bk_pop" href="#lgmd2a.REF.stramare.2010.585">Stramare et al 2010</a>, <a class="bk_pop" href="#lgmd2a.REF.wattjes.2010.2447">Wattjes et al 2010</a>, <a class="bk_pop" href="#lgmd2a.REF.kana.2014.278">Kana et al 2014</a>]. Muscle MRI is a useful tool in characterizing the degree of muscle atrophy and in some cases also the severity of the disease [<a class="bk_pop" href="#lgmd2a.REF.straub.2012.s42">Straub et al 2012</a>, <a class="bk_pop" href="#lgmd2a.REF.d_azmanera.2015.95">D&#x000ed;az-Manera et al 2015</a>].</div></li><li class="half_rhythm"><div>In the dominant form of calpainopathy, the paraspinal muscles were almost completely lost and replaced by fat [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>, <a class="bk_pop" href="#lgmd2a.REF.prahm.2017.358">Prahm et al 2017</a>].</div></li></ul></li><li class="half_rhythm"><div><b>Electromyogram (EMG)</b> pattern is typically myopathic (showing small polyphasic potentials), although a normal EMG can also be observed in presymptomatic individuals. Myotonia and spontaneous discharges are not present.</div></li></ul></div><div id="lgmd2a.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of calpainopathy <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CAPN3</i> (encoding proteolytic enzyme calpain-3) or a dominantly acting <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> for the <i>CAPN3</i> 21-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (c.643_663del21) by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (<a class="figpopup" href="/books/NBK1313/table/lgmd2a.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figlgmd2aTmoleculargenetictestingused" rid-ob="figoblgmd2aTmoleculargenetictestingused">Table 1</a>). <a href="#lgmd2a.Molecular_Genetic_Testing">Molecular genetic testing</a> approaches can include use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>, and <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>.</p><p>For calpainopathy, after the initial clinical workup and exclusion of the more common conditions with overlapping phenotypes, many experts recommend the use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> or more comprehensive testing as the immediate next step (see <a class="bk_pop" href="#lgmd2a.REF.thompson.2016.294">Thompson &#x00026; Straub [2016]</a>). If the process generates a clear result (<a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants or a dominantly acting <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>), no further diagnostic laboratory workup is required; if the result is unclear, imaging studies and muscle biopsy with protein immuno-analysis come into play. See <a href="#lgmd2a.Muscle_Biopsy"><b>Muscle Biopsy</b></a>.</p><div id="lgmd2a.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CAPN3</i> and other genes of interest (see <a href="#lgmd2a.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> varies by laboratory and are likely to change over time. (2) ) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</p><p>Note: (1) As compared to direct sequencing, more comprehensive genome testing was able to improve the detection rate of calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.ghaoui.2015.1424">Ghaoui et al 2015</a>, <a class="bk_pop" href="#lgmd2a.REF.savarese.2016.71">Savarese et al 2016</a>, <a class="bk_pop" href="#lgmd2a.REF.magri.2017.55">Magri et al 2017</a>]. (2) Many studies have revealed that this type of testing could be a time- and cost-effective method of diagnosing calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.bushby.2009.314">Bushby 2009</a>, <a class="bk_pop" href="#lgmd2a.REF.piluso.2011.1584">Piluso et al 2011</a>, <a class="bk_pop" href="#lgmd2a.REF.nigro.2012.196">Nigro &#x00026; Piluso 2012</a>, <a class="bk_pop" href="#lgmd2a.REF.nigro.2014.1">Nigro &#x00026; Savarese 2014</a>, <a class="bk_pop" href="#lgmd2a.REF.ghaoui.2015.1424">Ghaoui et al 2015</a>, <a class="bk_pop" href="#lgmd2a.REF.fadaee.2016.277">Fadaee et al 2016</a>, <a class="bk_pop" href="#lgmd2a.REF.kuhn.2016.743">Kuhn et al 2016</a>, <a class="bk_pop" href="#lgmd2a.REF.monies.2016.32">Monies et al 2016</a>, <a class="bk_pop" href="#lgmd2a.REF.seong.2016.484">Seong et al 2016</a>, <a class="bk_pop" href="#lgmd2a.REF.fattahi.2017.386">Fattahi et al 2017</a>, <a class="bk_pop" href="#lgmd2a.REF.magri.2017.55">Magri et al 2017</a>, <a class="bk_pop" href="#lgmd2a.REF.reddy.2017.243">Reddy et al 2017</a>].</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> may be recommended if a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> and/or more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing is not available and calpainopathy appears to be a likely diagnosis based on clinical findings. Sequence analysis of <i>CAPN3</i> is performed first, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</p><p>Targeted analysis for specific pathogenic variants can be performed first in individuals from certain populations/backgrounds. See <a href="#lgmd2a.Molecular_Genetics">Molecular Genetics</a>.</p><div id="lgmd2a.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Calpainopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1313/table/lgmd2a.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__lgmd2a.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_lgmd2a.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_lgmd2a.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_lgmd2a.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_lgmd2a.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;"><i>CAPN3</i></td><td headers="hd_h_lgmd2a.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_lgmd2a.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">&#x0003e;95%&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_lgmd2a.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_lgmd2a.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">&#x0003c;5%&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="lgmd2a.TF.1.1"><p class="no_margin">See <a href="/books/NBK1313/#lgmd2a.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="lgmd2a.TF.1.2"><p class="no_margin">See <a href="#lgmd2a.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="lgmd2a.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="lgmd2a.TF.1.4"><p class="no_margin">In individuals showing a severe calpain-3 protein deficiency in muscle biopsy, the probability of identifying pathogenic variants is about 84% [<a class="bk_pop" href="#lgmd2a.REF.fanin.2004.52">Fanin et al 2004</a>].</p></div></dd><dt>5. </dt><dd><div id="lgmd2a.TF.1.5"><p class="no_margin">In approximately 20%-30% of individuals with calpainopathy, only one <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was found, possibly because the second pathogenic variants are located in <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> regions outside the coding exons (e.g., introns or promoter) or are large genomic rearrangements [<a class="bk_pop" href="#lgmd2a.REF.fanin.2015.163">Fanin &#x00026; Angelini 2015</a>].</p></div></dd><dt>6. </dt><dd><div id="lgmd2a.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="lgmd2a.TF.1.7"><p class="no_margin">Large <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> rearrangements involving <i>CAPN3</i> have been recognized as causative of calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.richard.1999.1524">Richard et al 1999</a>], including out-of-frame <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of exons 2-8 [<a class="bk_pop" href="#lgmd2a.REF.joncourt.2003.667a">Joncourt et al 2003</a>, <a class="bk_pop" href="#lgmd2a.REF.krahn.2007.582">Krahn et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.todorova.2007.225">Todorova et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.ginjaar.2008.816a">Ginjaar et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.nascimbeni.2010.e1658">Nascimbeni et al 2010</a>], of exons 2-6 [<a class="bk_pop" href="#lgmd2a.REF.ginjaar.2008.816a">Ginjaar et al 2008</a>], or of the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#lgmd2a.REF.jaka.2014.448">Jaka et al 2014</a>].</p></div></dd></dl></div></div></div></div><div id="lgmd2a.Muscle_Biopsy"><h4>Muscle Biopsy</h4><p>Muscle biopsy should be used when molecular genetic analysis is not conclusive, or for diagnostic confirmation.</p><p>Note: For this disorder, the results of the specialized studies are much more useful for diagnosis than the routine histopathology of muscle biopsy.</p><p><b>Histopathology.</b> A variety of qualitative and quantitative morphologic changes may be observed, irrespective of the age of the individual at the time of biopsy. Wide variability can be observed even among individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the same <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant [<a class="bk_pop" href="#lgmd2a.REF.chae.2001.547">Chae et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2003.1929">Fanin et al 2003</a>].</p><ul><li class="half_rhythm"><div>Most individuals have the typical features of an active dystrophic process (increased fiber size variability, increased fibrosis, regenerating fibers, degenerating and necrotic fibers); others have mild and nonspecific myopathic features: increased central nuclei, fiber splitting, lobulated fibers (misaligned myofibrils that form a lobulated pattern), and type 1 fiber predominance [<a class="bk_pop" href="#lgmd2a.REF.vainzof.2003.624">Vainzof et al 2003</a>, <a class="bk_pop" href="#lgmd2a.REF.hermanov_.2006.424">Hermanov&#x000e1; et al 2006</a>, <a class="bk_pop" href="#lgmd2a.REF.keira.2007.513">Keira et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.luo.2011.402">Luo et al 2011</a>].</div></li><li class="half_rhythm"><div>The extent of muscle regeneration is less than is typically observed in other LGMDs [<a class="bk_pop" href="#lgmd2a.REF.fanin.2007a.609">Fanin et al 2007a</a>, <a class="bk_pop" href="#lgmd2a.REF.s_enz.2008.e3750">S&#x000e1;enz et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.hauerslev.2012.43">Hauerslev et al 2012</a>, <a class="bk_pop" href="#lgmd2a.REF.rosales.2013.731">Rosales et al 2013</a>].</div></li><li class="half_rhythm"><div>Eosinophilic myositis can be an early and transient feature of calpainopathy, which has been reported in individuals with increased CK levels and is not present in muscle from older <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with typical calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.brown.2006.875">Brown &#x00026; Amato 2006</a>, <a class="bk_pop" href="#lgmd2a.REF.krahn.2006b.905">Krahn et al 2006b</a>, <a class="bk_pop" href="#lgmd2a.REF.oflazer.2009.261">Oflazer et al 2009</a>, <a class="bk_pop" href="#lgmd2a.REF.krahn.2011.398">Krahn et al 2011</a>].</div></li><li class="half_rhythm"><div>There is considerable muscle fiber atrophy, which correlates with the clinical-functional severity of the disease [<a class="bk_pop" href="#lgmd2a.REF.fanin.2013.762">Fanin et al 2013</a>] and is significantly higher in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males than affected females [<a class="bk_pop" href="#lgmd2a.REF.fanin.2014.179">Fanin et al 2014</a>].</div></li><li class="half_rhythm"><div>Muscle biopsies from individuals with dominant calpainopathy show mild myopathic changes (including increased internal nuclei and fiber size variability, occasional necrotic fibers, ring fibers and fibrosis), which however do not reach in severity the level seen in individuals with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>].</div></li></ul><p><b>Specialized studies: calpain-3 immunoblot analysis.</b> Calpain-3 immunoblot testing is useful in the diagnosis of calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.pollitt.2001.287">Pollitt et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2009a.1432">Fanin et al 2009a</a>] and highly specific when calpain-3 protein is absent or severely reduced [<a class="bk_pop" href="#lgmd2a.REF.fanin.2004.52">Fanin et al 2004</a>, <a class="bk_pop" href="#lgmd2a.REF.krahn.2006a.444">Krahn et al 2006a</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2009b.598">Fanin et al 2009b</a>, <a class="bk_pop" href="#lgmd2a.REF.luo.2012.723">Luo et al 2012</a>]. Approximately 80% of individuals with pathogenic variants in <i>CAPN3</i> show a complete loss or a severe reduction of calpain-3 protein and 20%-30% have a normal amount of protein (but with loss of protein function) [<a class="bk_pop" href="#lgmd2a.REF.talim.2001.692">Talim et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2004.52">Fanin et al 2004</a>, <a class="bk_pop" href="#lgmd2a.REF.groen.2007.3237">Groen et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.milic.2007.148">Milic et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2009b.598">Fanin et al 2009b</a>, <a class="bk_pop" href="#lgmd2a.REF.perez.2010.502">Perez et al 2010</a>].</p><p>Note: The results of calpain-3 immunoblot analysis need to be interpreted with caution, as the analysis is neither completely specific (i.e., it can yield false positive results) nor completely sensitive (i.e., it can yield false negative results). Furthermore, the results must be considered in the context of other muscle proteins [<a class="bk_pop" href="#lgmd2a.REF.anderson.1999.1017">Anderson &#x00026; Davison 1999</a>] and optimal tissue preservation.</p><ul><li class="half_rhythm"><div>Lack of specificity:</div><ul><li class="half_rhythm"><div>Calpain-3 protein levels can be partially reduced in other muscular dystrophies, such as <a href="/books/n/gene/miyoshi/">dysferlinopathy</a> and <a href="/books/n/gene/udd/">Udd muscular dystrophy</a> (titinopathy) [<a class="bk_pop" href="#lgmd2a.REF.anderson.2000.553">Anderson et al 2000</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2001.660">Fanin et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.haravuori.2001.869">Haravuori et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.hackman.2002.492">Hackman et al 2002</a>].</div></li><li class="half_rhythm"><div>Although calpain-3 protein is extremely stable in muscle over time, its amount can be partially reduced by the artificial degradation that occurs when muscle tissue is handled or stored under conditions that promote rapid calpain-3 autolysis (e.g., partial thawing and exposure to moisture) [<a class="bk_pop" href="#lgmd2a.REF.anderson.1998.1169">Anderson et al 1998</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2003.1929">Fanin et al 2003</a>].</div></li></ul></li><li class="half_rhythm"><div>Lack of <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a>:</div><ul><li class="half_rhythm"><div>The most important pitfall in calpain-3 protein testing is that it is not completely sensitive in diagnosing LGMD2A [<a class="bk_pop" href="#lgmd2a.REF.talim.2001.692">Talim et al 2001</a>], since approximately 20%-30% of individuals with calpainopathy present a quantitative normal expression of the protein [<a class="bk_pop" href="#lgmd2a.REF.groen.2007.3237">Groen et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.milic.2007.148">Milic et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2009b.598">Fanin et al 2009b</a>], but a loss of function.</div></li><li class="half_rhythm"><div>When calpain immunoblotting testing shows complete or severe calpain-3 deficiency, the probability that an individual has calpainopathy is very high (84%); the probability progressively decreases as the amount of protein detected increases [<a class="bk_pop" href="#lgmd2a.REF.fanin.2004.52">Fanin et al 2004</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2009b.598">Fanin et al 2009b</a>].</div></li></ul></li></ul></div></div></div><div id="lgmd2a.Clinical_Characteristics"><h2 id="_lgmd2a_Clinical_Characteristics_">Clinical Characteristics</h2><div id="lgmd2a.Clinical_Description"><h3>Clinical Description</h3><p>Calpainopathy is characterized by symmetric and progressive weakness of proximal limb-girdle muscles. The age at onset of muscle weakness depends on <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and ranges from two to 40 years. Early motor milestones are usually normal. Intra- and interfamilial clinical variability ranges from severe to mild [<a class="bk_pop" href="#lgmd2a.REF.richard.1999.1524">Richard et al 1999</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2015.163">Fanin &#x00026; Angelini 2015</a>].</p><p>Three phenotypes of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> calpainopathy have been identified based on the distribution of muscle weakness and age at onset:</p><ul><li class="half_rhythm"><div><b>Pelvifemoral LGMD (Leyden-M&#x000f6;bius LGMD) <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>,</b> the most frequently observed calpainopathy phenotype. Muscle weakness is first evident in the pelvic girdle and later in the shoulder girdle. Onset can be early (age &#x0003c;12 years), adult (age 12-30 years), or late (age &#x0003e;30 years). Individuals with early onset and rapid disease course usually have pelvifemoral LGMD.</div></li><li class="half_rhythm"><div><b>Scapulohumeral LGMD (Erb LGMD) <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</b> Muscle weakness is first evident in the shoulder girdle and later in the pelvic girdle. Early onset is infrequent; the disease course is variable, but usually milder than that in the pelvifemoral phenotype.</div></li></ul><ul><li class="half_rhythm"><div><b>HyperCKemia.</b> HyperCKemia may be considered a presymptomatic stage of calpainopathy, as it is usually observed in children or in young persons with recessive calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.fanin.2009a.1432">Fanin et al 2009a</a>, <a class="bk_pop" href="#lgmd2a.REF.kyriakides.2010.767">Kyriakides et al 2010</a>]. Asymptomatic individuals, who are identified as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> following genetic studies, may develop symptoms of muscle weakness later.</div></li></ul><p>The <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of calpainopathy shows a variability of clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, ranging from almost asymptomatic to wheelchair dependent after age 60 years in a small number of cases [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>]. A prominent feature of such individuals is back pain and myalgia (present in &#x0003e;50% of the heterozygotes for the <i>CAPN3</i>
<a class="figpopup" href="/books/NBK1313/table/lgmd2a.T.selected_capn3_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figlgmd2aTselectedcapn3pathogenicvaria" rid-ob="figoblgmd2aTselectedcapn3pathogenicvaria">c.643_663del21</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>). The onset of muscle weakness is on average at age 34 years &#x02013;16 years later than British and Danish individuals with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> calpainopathy. Unquestionably, the clinical phenotype of the dominant calpainopathy is generally milder than in recessive calpainopathy.</p><p><b>The first clinical findings</b> of calpainopathy are usually:</p><ul><li class="half_rhythm"><div>The tendency to walk on tiptoe</div></li><li class="half_rhythm"><div>Difficulty in running</div></li><li class="half_rhythm"><div>Scapular winging</div></li></ul><p><b>Early stage of the disorder</b></p><ul><li class="half_rhythm"><div>The following are frequently observed:</div></li></ul><ul><li class="half_rhythm"><div>Waddling gait and slight hyperlordosis</div></li><li class="half_rhythm"><div>Symmetric weakness [<a class="bk_pop" href="#lgmd2a.REF.matsubara.2007.819">Matsubara et al 2007</a>] of proximal more than distal muscles in the limbs, trunk, and periscapular area. In particular, the gluteus maximus, thigh adductors, and posterior compartment of the limbs may be severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> [<a class="bk_pop" href="#lgmd2a.REF.fardeau.1996.295">Fardeau et al 1996</a>, <a class="bk_pop" href="#lgmd2a.REF.van_der_kooi.1996.1471">van der Kooi et al 1996</a>, <a class="bk_pop" href="#lgmd2a.REF.din_er.1997.222">Din&#x000e7;er et al 1997</a>, <a class="bk_pop" href="#lgmd2a.REF.topalo_lu.1997.212">Topalo&#x0011f;lu et al 1997</a>, <a class="bk_pop" href="#lgmd2a.REF.urtasun.1998.1735">Urtasun et al 1998</a>] and facial and neck muscles are usually spared.</div></li><li class="half_rhythm"><div>Scapular winging</div></li><li class="half_rhythm"><div>Marked laxity of the abdominal muscles [<a class="bk_pop" href="#lgmd2a.REF.bushby.1999.1403">Bushby 1999</a>, <a class="bk_pop" href="#lgmd2a.REF.pollitt.2001.287">Pollitt et al 2001</a>]</div></li><li class="half_rhythm"><div>Early Achilles tendon shortening and scoliosis</div></li></ul><ul><li class="half_rhythm"><div>Variable findings include:</div></li></ul><ul><li class="half_rhythm"><div>Muscle pain, exercise intolerance, and excessive lactate production in some individuals similar to that seen in a pseudo-metabolic myopathy [<a class="bk_pop" href="#lgmd2a.REF.p_nissonbesnier.1998.1078">P&#x000e9;nisson-Besnier et al 1998</a>, <a class="bk_pop" href="#lgmd2a.REF.pollitt.2001.287">Pollitt et al 2001</a>];</div></li><li class="half_rhythm"><div>Eosinophilic myositis, an early and transient feature, with increased CK level; it is not present in older individuals [<a class="bk_pop" href="#lgmd2a.REF.brown.2006.875">Brown &#x00026; Amato 2006</a>, <a class="bk_pop" href="#lgmd2a.REF.krahn.2006b.905">Krahn et al 2006b</a>, <a class="bk_pop" href="#lgmd2a.REF.krahn.2011.398">Krahn et al 2011</a>];</div></li><li class="half_rhythm"><div>Significant atrophy of the calf muscle or more rarely, calf hypertrophy;</div></li><li class="half_rhythm"><div>Rhabdomyolysis (and/or myoglobinuria) triggered by physical exercise; occasionally observed in asymptomatic individuals or in individuals with mild muscle involvement [<a class="bk_pop" href="#lgmd2a.REF.lahoria.2016.29">Lahoria &#x00026; Milone 2016</a>].</div></li></ul><p><b>Advanced stage of the disorder</b></p><ul><li class="half_rhythm"><div>Commonly observed:</div></li></ul><ul><li class="half_rhythm"><div>The inability to climb stairs, to rise up from a chair, to lift weights, or to get up from the floor</div></li><li class="half_rhythm"><div>Joint contractures (in the hips, knees, elbows, and fingers)</div></li></ul><ul><li class="half_rhythm"><div>Occasionally observed:</div></li></ul><ul><li class="half_rhythm"><div>Rigid spine [<a class="bk_pop" href="#lgmd2a.REF.pollitt.2001.287">Pollitt et al 2001</a>]</div></li><li class="half_rhythm"><div>Foot drop [<a class="bk_pop" href="#lgmd2a.REF.burke.2010.407">Burke et al 2010</a>]</div></li><li class="half_rhythm"><div>Respiratory insufficiency with reduced lung vital capacity to 30%-50% due to deficiency in diaphragmatic function, weakness in thoracic and abdominal muscles, and scoliosis [<a class="bk_pop" href="#lgmd2a.REF.fardeau.1996.295">Fardeau et al 1996</a>, <a class="bk_pop" href="#lgmd2a.REF.urtasun.1998.1735">Urtasun et al 1998</a>]. Compromised respiratory function was observed in 11% of individuals showing forced vital capacity lower than 50% [<a class="bk_pop" href="#lgmd2a.REF.richard.2016.248">Richard et al 2016</a>]. Some of those with severe respiratory insufficiency required the use of respiratory aids [<a class="bk_pop" href="#lgmd2a.REF.moriyoshimura.2017.465">Mori-Yoshimura et al 2017</a>].</div></li></ul><ul><li class="half_rhythm"><div>Uncommon: Cardiomyopathy. In most individuals cardiac symptoms that precede cardiac morbidity (including chest pain, lower limb oedema, palpitations) are not present, and cardiac abnormalities may be identified by echocardiography or electrocardiography. A systematic evaluation of heart involvement in a group of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals using cardiovascular magnetic resonance showed the lack of cardiac involvement in this disorder, even in individuals with advanced age and greater disorder severity [<a class="bk_pop" href="#lgmd2a.REF.quick.2015.661">Quick et al 2015</a>]. A few individuals have presented with non-life-threatening cardiac abnormalities [<a class="bk_pop" href="#lgmd2a.REF.richard.2016.248">Richard et al 2016</a>], atrial fibrillation, or variably impaired left ventricular function [<a class="bk_pop" href="#lgmd2a.REF.groen.2007.3237">Groen et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.okere.2013.e12">Okere et al 2013</a>, <a class="bk_pop" href="#lgmd2a.REF.moriyoshimura.2017.465">Mori-Yoshimura et al 2017</a>].</div></li></ul><p>Note: Neither intellectual disability nor macroglossia is associated with this disorder.</p><p><b>Progression and variability.</b> The asymptomatic stage may be relatively long in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, especially in females. In some individuals with calpainopathy, the onset of symptoms or the worsening of symptoms may be influenced by environmental factors, such as infectious disease, strenuous physical exercise, drug treatment, a traumatic event, or pregnancy [<a class="bk_pop" href="#lgmd2a.REF.s_enz.2005.732">S&#x000e1;enz et al 2005</a>].</p><p>The disease is invariably progressive and loss of ambulation occurs approximately ten to 30 years after the onset of symptoms (between ages 10 and 48 years) [<a class="bk_pop" href="#lgmd2a.REF.richard.1999.1524">Richard et al 1999</a>, <a class="bk_pop" href="#lgmd2a.REF.zatz.2003.532">Zatz et al 2003</a>, <a class="bk_pop" href="#lgmd2a.REF.s_enz.2005.732">S&#x000e1;enz et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.angelini.2010.41">Angelini et al 2010</a>, <a class="bk_pop" href="#lgmd2a.REF.gallardo.2011.97">Gallardo et al 2011</a>, <a class="bk_pop" href="#lgmd2a.REF.richard.2016.248">Richard et al 2016</a>]. In general, loss of independent ambulation occurs earlier in individuals with infantile onset of the disease [<a class="bk_pop" href="#lgmd2a.REF.gallardo.2011.97">Gallardo et al 2011</a>].</p><p>A more rapid progression of the disease was observed in males than in females [<a class="bk_pop" href="#lgmd2a.REF.de_paula.2002.825">de Paula et al 2002</a>, <a class="bk_pop" href="#lgmd2a.REF.zatz.2003.532">Zatz et al 2003</a>, <a class="bk_pop" href="#lgmd2a.REF.piluso.2005.686">Piluso et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.richard.2016.248">Richard et al 2016</a>]. In a natural history clinical study of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, a higher proportion of women were still walking as compared to men (72% versus 48% in men) [<a class="bk_pop" href="#lgmd2a.REF.richard.2016.248">Richard et al 2016</a>]. Males are more susceptible to muscle fiber atrophy than females and more affected by the consequent muscle weakness and clinical disability [<a class="bk_pop" href="#lgmd2a.REF.fanin.2014.179">Fanin et al 2014</a>].</p><p>Intrafamilial variability in the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> has been reported: in sibs with the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> the age at onset and the clinical course can vary considerably [<a class="bk_pop" href="#lgmd2a.REF.schessl.2008.54">Schessl et al 2008</a>], suggesting the influence of genetic background and environmental factors in determining the course of the disease.</p></div><div id="lgmd2a.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>There is no consistent <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation in calpainopathy, although <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> variants are generally associated with a severe phenotype and absent calpain-3 protein in muscle [<a class="bk_pop" href="#lgmd2a.REF.richard.1999.1524">Richard et al 1999</a>].</p><p>A single <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="figpopup" href="/books/NBK1313/table/lgmd2a.T.selected_capn3_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figlgmd2aTselectedcapn3pathogenicvaria" rid-ob="figoblgmd2aTselectedcapn3pathogenicvaria">c.643_663del21</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CAPN3</i> results in a dominantly inherited form of calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>].</p></div><div id="lgmd2a.Penetrance"><h3>Penetrance</h3><p>Nearly full <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is observed in adulthood. Some individuals remain asymptomatic until adulthood. Serum CK concentration is usually increased until the advanced stage of the disease.</p></div><div id="lgmd2a.Nomenclature"><h3>Nomenclature</h3><p>Calpainopathy was originally called LGMD2A because it was the first form of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> LGMD to be mapped [<a class="bk_pop" href="#lgmd2a.REF.beckmann.1991.141">Beckmann et al 1991</a>], but in recently revised nomenclature the designation LGMDR1 has been proposed (LGMDR refers to genetic types of LGMD showing autosomal recessive inheritance).</p><p><a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al [2016]</a> proposed that the recently characterized <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of calpainopathy associated with the c.643_663del21 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> be designated LGMD1I in the current nomenclature (LGMD1 refers to genetic types of LGMD showing dominant inheritance), and designated LGMDD3 in revised nomenclature (LGMDD refers to genetic types of LGMD showing autosomal dominant inheritance).</p><p>As both recessive and dominant forms are associated with calpain-3 abnormality, calpainopathy is the preferred term for this disorder.</p></div><div id="lgmd2a.Prevalence"><h3>Prevalence</h3><p>Calpainopathy is considered the most common form of LGMD [<a class="bk_pop" href="#lgmd2a.REF.bushby.2003">Bushby &#x00026; Beckmann 2003</a>, <a class="bk_pop" href="#lgmd2a.REF.guglieri.2008.258">Guglieri et al 2008</a>], representing approximately 30% of LGMD cases, depending on the geographic region [<a class="bk_pop" href="#lgmd2a.REF.chou.1999.1015">Chou et al 1999</a>, <a class="bk_pop" href="#lgmd2a.REF.zatz.2000.511">Zatz et al 2000</a>]. Estimates based on molecular data indicate that the frequency of calpainopathy ranges from 6%-8% of all LGMD in Australia, Korea, and Germany [<a class="bk_pop" href="#lgmd2a.REF.hanisch.2007.157">Hanisch et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.shin.2007.463">Shin et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.lo.2008.34">Lo et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.ghaoui.2015.1424">Ghaoui et al 2015</a>, <a class="bk_pop" href="#lgmd2a.REF.seong.2016.484">Seong et al 2016</a>], to 4%-12% in the USA [<a class="bk_pop" href="#lgmd2a.REF.chou.1999.1015">Chou et al 1999</a>, <a class="bk_pop" href="#lgmd2a.REF.moore.2006.995">Moore et al 2006</a>, <a class="bk_pop" href="#lgmd2a.REF.reddy.2017.243">Reddy et al 2017</a>], 13% in Denmark [<a class="bk_pop" href="#lgmd2a.REF.duno.2008.935">Duno et al 2008</a>], 16% in Saudi Arabia [<a class="bk_pop" href="#lgmd2a.REF.monies.2016.32">Monies et al 2016</a>], 17%-18% in Mexico and northern China [<a class="bk_pop" href="#lgmd2a.REF.g_mezd_az.2012.338">G&#x000f3;mez-D&#x000ed;az et al 2012</a>, <a class="bk_pop" href="#lgmd2a.REF.mahmood.2013.1907">Mahmood et al 2013</a>], 21% in the Netherlands [<a class="bk_pop" href="#lgmd2a.REF.van_der_kooi.2007.2125">van der Kooi et al 2007</a>], 21%-26% in Japan and Lithuania [<a class="bk_pop" href="#lgmd2a.REF.kawai.1998.1493">Kawai et al 1998</a>, <a class="bk_pop" href="#lgmd2a.REF.minami.1999.31">Minami et al 1999</a>, <a class="bk_pop" href="#lgmd2a.REF.luo.2011.402">Luo et al 2011</a>, <a class="bk_pop" href="#lgmd2a.REF.inashkina.2016.200">Inashkina et al 2016</a>], 24% in Iran [<a class="bk_pop" href="#lgmd2a.REF.fattahi.2017.386">Fattahi et al 2017</a>], 25%-35% in Italy, Germany, and northern England [<a class="bk_pop" href="#lgmd2a.REF.piluso.2005.686">Piluso et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.guglieri.2008.258">Guglieri et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2009a.1432">Fanin et al 2009a</a>, <a class="bk_pop" href="#lgmd2a.REF.norwood.2009.3175">Norwood et al 2009</a>, <a class="bk_pop" href="#lgmd2a.REF.kuhn.2016.743">Kuhn et al 2016</a>, <a class="bk_pop" href="#lgmd2a.REF.magri.2017.55">Magri et al 2017</a>], 32% in Brazil [<a class="bk_pop" href="#lgmd2a.REF.zatz.2000.511">Zatz et al 2000</a>], 33% in Czech Republic [<a class="bk_pop" href="#lgmd2a.REF.stehl_kov_.2014.154">Stehl&#x000ed;kov&#x000e1; et al 2014</a>], 40%-50% in France, Turkey, Spain, India, Slovenia, and Bulgaria [<a class="bk_pop" href="#lgmd2a.REF.din_er.1997.222">Din&#x000e7;er et al 1997</a>, <a class="bk_pop" href="#lgmd2a.REF.richard.1997.1128">Richard et al 1997</a>, <a class="bk_pop" href="#lgmd2a.REF.meznaricpetrusa.2002.73a">Meznaric-Petrusa et al 2002</a>, <a class="bk_pop" href="#lgmd2a.REF.georgieva.2005.399">Georgieva et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.s_enz.2005.732">S&#x000e1;enz et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.balci.2006.293">Balci et al 2006</a>, <a class="bk_pop" href="#lgmd2a.REF.todorova.2007.225">Todorova et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.pathak.2010.549">Pathak et al 2010</a>], and 80% in Basque country, Russia, and Poland [<a class="bk_pop" href="#lgmd2a.REF.urtasun.1998.1735">Urtasun et al 1998</a>, <a class="bk_pop" href="#lgmd2a.REF.pogoda.2000.295">Pogoda et al 2000</a>, <a class="bk_pop" href="#lgmd2a.REF.dadali.2010.79">Dadali et al 2010</a>, <a class="bk_pop" href="#lgmd2a.REF.dorobek.2015.637">Dorobek et al 2015</a>].</p><p>A genetic epidemiologic study in northeastern Italy estimated that calpainopathy has a prevalence of approximately 1:100,000 inhabitants (corresponding to a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of ~1:160) [<a class="bk_pop" href="#lgmd2a.REF.fanin.2005.218">Fanin et al 2005</a>]. Another study in southern Italy estimated the prevalence of calpainopathy at 1:42,700 inhabitants (corresponding to a carrier frequency of ~1:103) [<a class="bk_pop" href="#lgmd2a.REF.piluso.2005.686">Piluso et al 2005</a>].</p><p>Higher prevalence rates have been calculated in small and genetically <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> communities; the prevalence of the disease has been estimated at 48 per million in the Reunion Island [<a class="bk_pop" href="#lgmd2a.REF.fardeau.1996.295">Fardeau et al 1996</a>], 69 per million in Basque country [<a class="bk_pop" href="#lgmd2a.REF.urtasun.1998.1735">Urtasun et al 1998</a>], 1900 per million in the M&#x000f2;cheni community in the Alps [<a class="bk_pop" href="#lgmd2a.REF.fanin.2012.601">Fanin et al 2012</a>], 4300 per million in the Tlaxcala village in central Mexico (with a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of 1:11) [<a class="bk_pop" href="#lgmd2a.REF.pantojamelendez.2017.e0170280">Pantoja-Melendez et al 2017</a>], and 13000 per million in the Amish population of Indiana [<a class="bk_pop" href="#lgmd2a.REF.young.1992.1370">Young et al 1992</a>, <a class="bk_pop" href="#lgmd2a.REF.richard.1995.27">Richard et al 1995</a>].</p><p>Three general population screening studies of the most common <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (<a class="figpopup" href="/books/NBK1313/table/lgmd2a.T.selected_capn3_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figlgmd2aTselectedcapn3pathogenicvaria" rid-ob="figoblgmd2aTselectedcapn3pathogenicvaria">c.550delA</a>) in Lithuania, Croatia, and Poland resulted in the identification of healthy carriers, corresponding to estimated <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequencies of 1:175, 1:133, and 1:124 respectively [<a class="bk_pop" href="#lgmd2a.REF.cankiklain.2004.152">Canki-Klain et al 2004</a>, <a class="bk_pop" href="#lgmd2a.REF.dorobek.2015.637">Dorobek et al 2015</a>, <a class="bk_pop" href="#lgmd2a.REF.inashkina.2016.200">Inashkina et al 2016</a>].</p></div></div><div id="lgmd2a.Genetically_Related_Allelic_Disor"><h2 id="_lgmd2a_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are associated with pathogenic variants in <i>CAPN3</i>.</p></div><div id="lgmd2a.Differential_Diagnosis"><h2 id="_lgmd2a_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Other forms of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> limb-girdle muscular dystrophy</b> (LGMD2 or LGMDR in revised nomenclature; see <a href="http://omim.org/phenotypicSeries/PS253600" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM Phenotypic Series: Muscular dystrophy, limb-girdle, autosomal recessive</a>) cannot be distinguished from calpainopathy on clinical grounds, although calpainopathy generally has a later onset and is relatively mild, particularly by comparison with sarcoglycanopathies [<a class="bk_pop" href="#lgmd2a.REF.nigro.2014.1">Nigro &#x00026; Savarese 2014</a>]. Multigene panels are increasingly used to identify pathogenic variants and confirm a diagnosis of a specific form of LGMD. If this approach is not available, immunoblot analysis of muscle biopsy for candidate proteins (sarcoglycans, dysferlin, telethonin, titin) can help establish the correct diagnosis.</p><p><a href="/books/n/gene/fsh/"><b>Facioscapulohumeral muscular dystrophy</b></a>
<b>(FSHD)</b> shares some clinical and laboratory features with Erb LGMD (one of the calpainopathy phenotypes) [<a class="bk_pop" href="#lgmd2a.REF.leidenroth.2012.999">Leidenroth et al 2012</a>, <a class="bk_pop" href="#lgmd2a.REF.sacconi.2012.41">Sacconi et al 2012</a>] in which muscle weakness with onset in the shoulder girdle, scapular winging, elevated serum CK concentration, and nonspecific myopathic changes on muscle biopsy can be seen. However, facial muscle weakness and asymmetric scapular muscle involvement, which can be observed in FSHD, are uncommon in calpainopathy. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; although some controversy remains, FSHD is likely caused by inappropriate expression of the double homeobox-containing <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>DUX4</i> in muscle cells.</p><p>In a few cases, both a contracted D4Z4 fragment (<i>DUX4</i>) and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CAPN3</i> have been identified in association with limb-girdle and facioscapulohumeral muscular dystrophy-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#lgmd2a.REF.pastorello.2012.230">Pastorello et al 2012</a>, <a class="bk_pop" href="#lgmd2a.REF.simeoni.2015.292">Simeoni et al 2015</a>].</p><p><a href="/books/n/gene/dbmd/"><b>Dystrophinopathy</b></a><b>.</b> The dystrophinopathies include a spectrum of muscle disease caused by pathogenic variants in <i>DMD</i>, which encodes the protein dystrophin. Dystrophinopathy was diagnosed in about 17% of individuals with a clinical diagnosis of LGMD (31% of males and 13% of females) [<a class="bk_pop" href="#lgmd2a.REF.arikawa.1991.1491">Arikawa et al 1991</a>], emphasizing the clinical overlap between LGMD and dystrophinopathy. The correct diagnosis can be established in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>DMD</i>.</p><p><a href="/books/n/gene/dbmd/"><b>Becker muscular dystrophy</b></a>
<b>(BMD),</b> muscle disease at the mild end of the dystrophinopathy spectrum, should be considered in males with clinical and laboratory features that are in common with calpainopathy: onset of weakness in the lower girdle muscles in adolescence or adulthood and elevated serum CK concentrations. An <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> pattern of inheritance or the presence of heart involvement (mainly dilated cardiomyopathy), distinguish BMD from calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.shaboodien.2015.152">Shaboodien et al 2015</a>].</p><p><b>Metabolic myopathy.</b> Calpainopathy has been reported in individuals with asthenia, myalgias, exercise intolerance, lower-limb proximal muscle weakness, and excessive lactate production after aerobic exercise [<a class="bk_pop" href="#lgmd2a.REF.p_nissonbesnier.1998.1078">P&#x000e9;nisson-Besnier et al 1998</a>, <a class="bk_pop" href="#lgmd2a.REF.pollitt.2001.287">Pollitt et al 2001</a>]. In metabolic myopathies muscle weakness can be either distal (e.g., glycogenosis type 3) or proximal (e.g., glycogenosis type 2) and may be transitory (e.g., CPT-2 deficiency) or permanent (e.g., glycogenosis type 2 and glycogenosis type 5). Metabolic myopathies are also different from calpainopathy because of vacuolar muscle biopsy histopathologic features (e.g., glycogen storage).</p><p>The association between rhabdomyolysis and LGMD is less recognized than the association between rhabdomyolysis and metabolic myopathies (i.e. CPT2 deficiency); this often leads to misdiagnosis or delayed diagnosis. Some individuals with calpainopathy presented rhabdomyolytic episodes, mild muscle weakness, and persistent elevation of CK levels even at distance from a myoglobinuric episode (whereas in metabolic myopathies CK levels between myoglobinuric episodes is usually normal) [<a class="bk_pop" href="#lgmd2a.REF.lahoria.2016.29">Lahoria &#x00026; Milone 2016</a>].</p><p><b>Myopathy with contractures.</b> The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of calpainopathy may include muscle weakness with severe tendon contractures [<a class="bk_pop" href="#lgmd2a.REF.pollitt.2001.287">Pollitt et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.gallardo.2011.97">Gallardo et al 2011</a>, <a class="bk_pop" href="#lgmd2a.REF.richard.2016.248">Richard et al 2016</a>], raising the possibility of <a href="/books/n/gene/edmd/">Emery-Dreifuss muscular dystrophy</a>.</p></div><div id="lgmd2a.Management"><h2 id="_lgmd2a_Management_">Management</h2><div id="lgmd2a.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with calpainopathy, the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Complete physical evaluation including the grading of muscle strength in single upper, lower, proximal, and distal muscles and the analysis of several functional performances</div></li><li class="half_rhythm"><div>Orthopedic examination when gait is severely impaired</div></li><li class="half_rhythm"><div>When walking ability is compromised, an evaluation for physical therapy and orthoses, especially in later stages of the disease</div></li><li class="half_rhythm"><div>Baseline pulmonary function testing (including forced vital capacity measurement)</div></li><li class="half_rhythm"><div>Baseline cardiac evaluation including echocardiogram</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="lgmd2a.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Appropriate management, tailored to each individual, can improve quality of life and prolong survival. The general approach is based on the typical progression and complications of individuals with LGMD as described by <a class="bk_pop" href="#lgmd2a.REF.mcdonald.1995.s117">McDonald et al [1995]</a>, <a class="bk_pop" href="#lgmd2a.REF.bushby.1999.1403">Bushby [1999]</a>, and <a class="bk_pop" href="#lgmd2a.REF.norwood.2007.1305">Norwood et al [2007]</a>, and revised by the Committee of the American Academy of Neurology [<a class="bk_pop" href="#lgmd2a.REF.narayanaswami.2014.1453">Narayanaswami et al 2014</a>]:</p><ul><li class="half_rhythm"><div>A passive physical therapy program [<a class="bk_pop" href="#lgmd2a.REF.oygard.2011.20">Oygard et al 2011</a>] and stretching exercises should be instituted early after diagnosis to promote mobility, prolong walking, and slow the disease progression, in particular by maintaining joint flexibility. Individuals usually benefit from strengthening and gentle [<a class="bk_pop" href="#lgmd2a.REF.sveen.2013.163">Sveen et al 2013</a>], low-impact aerobic exercise (swimming, stationary bicycling) with a supervised sub-maximal effort, which improves cardiovascular performance, increases muscle efficiency, and lessens muscle fatigue. Although there are no specific reports on supportive care, physical and occupational therapies are important [<a class="bk_pop" href="#lgmd2a.REF.eagle.2002.975">Eagle 2002</a>].</div></li><li class="half_rhythm"><div>Avoidance of prolonged immobility is recommended.</div></li><li class="half_rhythm"><div>Technical aids can also compensate for the loss of certain motor abilities; canes, walkers, orthotics, and wheelchairs enable individuals to regain independence. The use of knee-ankle-foot orthoses at bedtime is recommended to prevent contractures. Scoliosis occurs mainly after wheelchair dependence and attention should be paid to seating [<a class="bk_pop" href="#lgmd2a.REF.norwood.2007.1305">Norwood et al 2007</a>].</div></li><li class="half_rhythm"><div>Surgical intervention may be required for correction of orthopedic complications including foot deformities, scoliosis, and Achilles tendon contractures. Occasionally, scapular fixation may be required for particularly problematic scapular winging.</div></li><li class="half_rhythm"><div>In the late stage of the disease, chronic respiratory insufficiency may occur and the use of respiratory aids may be indicated to prolong survival [<a class="bk_pop" href="#lgmd2a.REF.pollitt.2001.287">Pollitt et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.norwood.2007.1305">Norwood et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.dangelo.2011.54">D'Angelo et al 2011</a>, <a class="bk_pop" href="#lgmd2a.REF.richard.2016.248">Richard et al 2016</a>, <a class="bk_pop" href="#lgmd2a.REF.moriyoshimura.2017.465">Mori-Yoshimura et al 2017</a>].</div><ul><li class="half_rhythm"><div>Individuals should be monitored for signs of nocturnal hypoventilation (sleep disturbances, early morning headache, daytime drowsiness).</div></li><li class="half_rhythm"><div>Overnight pulse oxymetry is recommended if forced vital capacity is lower than 60% and the demonstration of nocturnal hypoventilation should lead to noninvasive nocturnal ventilation [<a class="bk_pop" href="#lgmd2a.REF.norwood.2007.1305">Norwood et al 2007</a>].</div></li><li class="half_rhythm"><div>Intervention in the form of nocturnal ventilator assistance for respiratory failure (by noninvasive positive pressure ventilation, NIV, by nasal masks) may be life saving in severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#lgmd2a.REF.dirik.2001.235">Dirik et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.hashiguchi.2014.1097">Hashiguchi et al 2014</a>, <a class="bk_pop" href="#lgmd2a.REF.moriyoshimura.2017.465">Mori-Yoshimura et al 2017</a>].</div></li><li class="half_rhythm"><div>Wheelchair-bound individuals may also develop weak cough efforts, placing them at risk of atelectasia, pneumonia, progressive mismatch, and respiratory failure.</div></li><li class="half_rhythm"><div>Annual influenza vaccination and prompt treatment for chest and respiratory infections should be eventually addressed using a mechanical in-ex-sufflator [<a class="bk_pop" href="#lgmd2a.REF.moriyoshimura.2017.465">Mori-Yoshimura et al 2017</a>].</div></li></ul></li><li class="half_rhythm"><div>Social and emotional support help to improve the quality of life, to maximize a sense of social involvement and productivity, and to reduce the sense of social isolation [<a class="bk_pop" href="#lgmd2a.REF.eggers.1998.4">Eggers &#x00026; Zatz 1998</a>].</div></li><li class="half_rhythm"><div>Clinicians should anticipate and facilitate decision-making for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and their families as the disease progresses, including decisions regarding loss of mobility and need of assistance with activities of daily living, medical complications, and end-of-life care [<a class="bk_pop" href="#lgmd2a.REF.narayanaswami.2014.1453">Narayanaswami et al 2014</a>].</div></li></ul></div><div id="lgmd2a.Prevention_of_Secondary_Manifesta"><h3>Prevention of Secondary Manifestations</h3><p>There are a number of measures that decrease disease manifestations in a symptomatic individual: control of weight gain, prevention of joint contractures by means of physical therapy and stretching exercises, and in the advanced stage, control of respiratory insufficiency. Physical therapy and stretching exercises can help to slow disease progression; therefore, a physical therapy program should be instituted early after diagnosis.</p></div><div id="lgmd2a.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Annual monitoring of muscle strength, joint range of motion, and respiratory function:</div><ul><li class="half_rhythm"><div>Monitoring for orthopedic complications, such as foot deformities, scoliosis, and Achilles tendon contractures</div></li><li class="half_rhythm"><div>Referral for pulmonary evaluation (eventually including pulmonary function tests) when there are complaints of excessive daytime somnolence, non-restorative sleep, early morning headache [<a class="bk_pop" href="#lgmd2a.REF.narayanaswami.2014.1453">Narayanaswami et al 2014</a>]. Measurement of forced vital capacity should be made in sitting and supine position.</div></li></ul></li><li class="half_rhythm"><div>Examination of cardiac function in the advanced stage of disease (although it is not frequently compromised) [<a class="bk_pop" href="#lgmd2a.REF.dirik.2001.235">Dirik et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.okere.2013.e12">Okere et al 2013</a>].</div></li></ul></div><div id="lgmd2a.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Strenuous and eccentric muscle exercise should be discouraged as it exacerbates muscle necrosis and could precipitate the onset of weakness or accelerate muscle wasting. Although individuals with minimal muscle weakness and functional limitation may be able to perform strenuous exercise, in some cases this may result in rhabdomyolysis and myoglobinuria [<a class="bk_pop" href="#lgmd2a.REF.lahoria.2016.29">Lahoria &#x00026; Milone 2016</a>] which may lead to severe complications such as acute renal failure and compartment syndrome.</p><p>Body weight should be controlled to avoid obesity as well as excessive weight loss (atrophy of muscles can be accelerated by loss of muscle proteins).</p><p>Physical trauma, bone fractures, and prolonged immobility can induce disuse atrophy and thus should be avoided.</p><p>Although no association of the disease with malignant hyperthermia is reported, the use of succinylcholine and halogenated anesthetic agents should be avoided when possible (see <a href="/books/n/gene/mhs/">Malignant Hyperthermia Susceptibility</a>).</p><p>While the specific mechanism whereby cholesterol-lowering agents (e.g., statins) may produce muscle damage causing pain or weakness is unknown, such drugs should be avoided when possible.</p></div><div id="lgmd2a.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family in order to identify as early as possible those who would benefit from initiation of evaluation and subsequent surveillance. With the associated intrafamilial <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> variability, the possibility of calpainopathy should not be excluded in sibs on the basis of absence of symptoms alone.</p><p>See <a href="#lgmd2a.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="lgmd2a.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Women with calpainopathy do not have impaired uterine smooth muscle strength or function and typically have uncomplicated pregnancies. A higher incidence of abnormal fetal presentation was reported in wheelchair-bound individuals with LGMD [<a class="bk_pop" href="#lgmd2a.REF.awater.2012.153">Awater et al 2012</a>]. Epidural blockade can be difficult in those with severe spine deformities and appropriate general anaesthesia may be necessary. About half of persons with LGMD reported deterioration of clinical symptoms in pregnancy [<a class="bk_pop" href="#lgmd2a.REF.awater.2012.153">Awater et al 2012</a>].</p></div><div id="lgmd2a.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="lgmd2a.Genetic_Counseling"><h2 id="_lgmd2a_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="lgmd2a.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Calpainopathy is typically inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Less commonly, calpainopathy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="lgmd2a.Risk_to_Family_Members__Autosomal"><h3>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CAPN3</i>.</div></li><li class="half_rhythm"><div>In populations with a high rate of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>, the reproductive partner of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual may be a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, in which case the risk to the offspring of being affected is 50%.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><div id="lgmd2a.Carrier_Heterozygote_Detection"><h4>Carrier (Heterozygote) Detection</h4><p>Carrier testing for at-risk family members requires prior identification of the <i>CAPN3</i> pathogenic variants in the family.</p><p>If the reproductive partner of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual (or known <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) belongs to the same genetic isolate and is therefore at an increased risk of being a carrier of an <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (see <a href="#lgmd2a.Prevalence">Prevalence</a>), <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> may be requested and is generally done by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p></div></div><div id="lgmd2a.Risk_to_Family_Members__Autosomal_1"><h3>Risk to Family Members &#x02013; Autosomal Dominant Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>To date, all individuals diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> calpainopathy inherited a <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent. Clinical variability has been reported within families [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>] and a heterozygous parent may or may not have clinical features of calpainopathy.</div></li><li class="half_rhythm"><div>To date, <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> occurrence of the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of calpainopathy has not been reported.</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent (though theoretically possible, no instances of germline mosaicism have been reported).</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> calpainopathy may appear to be negative because of early death of the parent before the onset of symptoms, late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent (see <a href="#lgmd2a.Penetrance">Penetrance</a>), or subclinical manifestations of calpainopathy in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>]. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or is known to be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to sibs is 50%. Intrafamilial clinical variability ranging from asymptomatic to wheelchair dependence has been observed [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>].</div></li><li class="half_rhythm"><div>If the <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that of the general population (though still &#x0003c;1%) because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div>If both parents are clinically unaffected but have not been tested for the <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are still at increased risk for calpainopathy because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> calpainopathy has a 50% chance of inheriting the <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="lgmd2a.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#lgmd2a.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers (e.g., asymptomatic relatives of known affected individuals).</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="lgmd2a.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible. Prenatal diagnosis for calpainopathy has been requested from <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> couples, who previously had an affected child [<a class="bk_pop" href="#lgmd2a.REF.restagno.1996.173">Restagno et al 1996</a>].</p></div></div><div id="lgmd2a.Resources"><h2 id="_lgmd2a_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Association Francaise contre les Myopathies (AFM)</b></div><div>1 Rue de l'International</div><div>BP59</div><div>Evry cedex 91002</div><div>France</div><div><b>Phone:</b> +33 01 69 47 28 28</div><div><b>Email:</b> dmc@afm.genethon.fr</div><div><a href="http://www.afm-telethon.fr" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.afm-telethon.fr </a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy UK</b></div><div>61A Great Suffolk Street</div><div>London SE1 0BU </div><div>United Kingdom</div><div><b>Phone:</b> 0800 652 6352 (toll-free); 020 7803 4800</div><div><b>Email:</b> info@musculardystrophyuk.org</div><div><a href="http://www.musculardystrophyuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.musculardystrophyuk.org</a></div></li></ul></div><div id="lgmd2a.Molecular_Genetics"><h2 id="_lgmd2a_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="lgmd2a.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Calpainopathy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1313/table/lgmd2a.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__lgmd2a.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_lgmd2a.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_lgmd2a.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_lgmd2a.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_lgmd2a.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_lgmd2a.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_lgmd2a.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_lgmd2a.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/825" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CAPN3</i></a></td><td headers="hd_b_lgmd2a.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=825" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q15<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_lgmd2a.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P20807" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Calpain-3</a></td><td headers="hd_b_lgmd2a.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/CAPN3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CAPN3 homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_lgmd2a.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CAPN3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CAPN3</a></td><td headers="hd_b_lgmd2a.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CAPN3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CAPN3</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="lgmd2a.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="lgmd2a.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Calpainopathy (<a href="/omim/114240,253600" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1313/table/lgmd2a.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__lgmd2a.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/114240" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">114240</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CALPAIN 3; CAPN3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/253600" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">253600</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</td></tr></tbody></table></div></div><p><b>Gene structure.</b> The longest <i>CAPN3</i> transcript variant comprises 24 exons and covers a <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> region of 50 kb. It is expressed as a 3.5-kb transcript (2466 coding nucleotides). <i>CAPN3</i> encodes a number of alternatively spliced transcripts [<a class="bk_pop" href="#lgmd2a.REF.herasse.1999.4047">Herasse et al 1999</a>]. Alternate promoters and alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> result in multiple transcript variants encoding different <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> and some variants are ubiquitously expressed [<a class="bk_pop" href="#lgmd2a.REF.de_tullio.2003.689">De Tullio et al 2003</a>, <a class="bk_pop" href="#lgmd2a.REF.kawabata.2003.623">Kawabata et al 2003</a>].</p><p>Muscle tissue expresses only one isoform (the full-length transcript), whereas leukocytes express four different transcripts (produced by alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of exons 6,15,16), all of which lack <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 15. Since peripheral blood instead of muscle tissue has increasingly been used to obtain <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> for <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> sequencing, the results of the two analyses could be discordant in some cases [<a class="bk_pop" href="#lgmd2a.REF.bl_zquez.2008.173">Bl&#x000e1;zquez et al 2008</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1313/#lgmd2a.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> According to the Leiden Muscular Dystrophy Mutation Database, more than 490 pathogenic variants have been reported; they are distributed throughout <i>CAPN3</i> [<a class="bk_pop" href="#lgmd2a.REF.anderson.1998.1169">Anderson et al 1998</a>, <a class="bk_pop" href="#lgmd2a.REF.de_paula.2002.825">de Paula et al 2002</a>, <a class="bk_pop" href="#lgmd2a.REF.zatz.2003.532">Zatz et al 2003</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2004.52">Fanin et al 2004</a>].</p><p>Most pathogenic variants are single-nucleotide changes. Approximately 70% of abnormal alleles are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants; the remaining are a variety of <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants (small deletions or insertions causing frameshift and premature stop codon, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants) [<a class="bk_pop" href="#lgmd2a.REF.richard.1999.1524">Richard et al 1999</a>].</p><p>About 25% of pathogenic variants in <i>CAPN3</i> are located at <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>-<a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> boundaries and cause aberrant <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> [<a class="bk_pop" href="#lgmd2a.REF.krahn.2007.582">Krahn et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.bl_zquez.2008.173">Bl&#x000e1;zquez et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.nascimbeni.2010.e1658">Nascimbeni et al 2010</a>].</p><p>Many deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> pathogenetic variants that disrupt the correct <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> can be overlooked by sequencing of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA [<a class="bk_pop" href="#lgmd2a.REF.krahn.2007.582">Krahn et al 2007</a>]; their identification may require the sequencing of <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> obtained from muscle or blood tissues [<a class="bk_pop" href="#lgmd2a.REF.krahn.2006a.444">Krahn et al 2006a</a>, <a class="bk_pop" href="#lgmd2a.REF.bl_zquez.2008.173">Bl&#x000e1;zquez et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.nascimbeni.2010.e1658">Nascimbeni et al 2010</a>].</p><p>Deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> variants causing a pseudo-exonization of an intronic sequence have been reported [<a class="bk_pop" href="#lgmd2a.REF.bl_zquez.2008.173">Bl&#x000e1;zquez et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.bl_zquez.2013.1387">Bl&#x000e1;zquez et al 2013</a>], as well as large <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions, the most frequent of which is an out-of-frame 31,012-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of exons 2-8 (c.309+4469_c.1116-1204del) [<a class="bk_pop" href="#lgmd2a.REF.richard.1999.1524">Richard et al 1999</a>, <a class="bk_pop" href="#lgmd2a.REF.joncourt.2003.667a">Joncourt et al 2003</a>, <a class="bk_pop" href="#lgmd2a.REF.krahn.2007.582">Krahn et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.todorova.2007.225">Todorova et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.ginjaar.2008.816a">Ginjaar et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.nascimbeni.2010.e1658">Nascimbeni et al 2010</a>, <a class="bk_pop" href="#lgmd2a.REF.piluso.2011.1584">Piluso et al 2011</a>, <a class="bk_pop" href="#lgmd2a.REF.bartoli.2012.99">Bartoli et al 2012</a>]. Since this deletion recurs in calpainopathy in individuals from different ethnic backgrounds, it is probably due to independent mutation events [<a class="bk_pop" href="#lgmd2a.REF.todorova.2007.225">Todorova et al 2007</a>].</p><p>Genomic rearrangements of Alu elements [<a class="bk_pop" href="#lgmd2a.REF.salem.2012.92">Salem et al 2012</a>], the entire <i>CAPN3</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> [<a class="bk_pop" href="#lgmd2a.REF.jaka.2014.448">Jaka et al 2014</a>], and synonymous codon variants [<a class="bk_pop" href="#lgmd2a.REF.richard.1995.259">Richard &#x00026; Beckmann 1995</a>] have been occasionally reported.</p><p>A single <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> c.643_663del21 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CAPN3</i> results in a dominantly inherited form of calpainopathy [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>]. Of note, this variant has been identified in compound heterozygosity with other pathogenic variants in <i>CAPN3</i>, including c.2362_2363delinsTCATCT, c.550delA, p.Ala45Thr, and p.Asp419Gly [<a class="bk_pop" href="#lgmd2a.REF.richard.1997.1128">Richard et al 1997</a>, <a class="bk_pop" href="#lgmd2a.REF.groen.2007.3237">Groen et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.s_enz.2017.e7">S&#x000e1;enz &#x00026; L&#x000f3;pez de Munain 2017</a>].</p><p>Many pathogenic variants have been observed repeatedly in different populations; the c.550delA <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is the most common <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (accounting for up to 75% of abnormal alleles) among individuals from different European countries [<a class="bk_pop" href="#lgmd2a.REF.richard.1999.1524">Richard et al 1999</a>].</p><p>Pathogenic variants that recur in the following populations are most likely the result of a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> followed by genetic isolation; especially in small populations, the accumulation of specific pathogenic variants (also called "<a class="def" href="/books/n/gene/glossary/def-item/private/">private</a> mutations") may be explained by <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> associated with historical, demographic, or cultural/religious factors:</p><ul><li class="half_rhythm"><div>Reunion Island in the Indian Ocean (c.946-1G&#x0003e;A) [<a class="bk_pop" href="#lgmd2a.REF.fardeau.1996.295">Fardeau et al 1996</a>]</div></li><li class="half_rhythm"><div>Old Order Amish community in northern Indiana, USA (p.Arg769Gln) [<a class="bk_pop" href="#lgmd2a.REF.young.1992.1370">Young et al 1992</a>, <a class="bk_pop" href="#lgmd2a.REF.richard.1995.27">Richard et al 1995</a>]</div></li><li class="half_rhythm"><div>Russia, Croatia, Turkey, Czech Republic, Bulgaria, Germany, Italy, Poland (c.550delA) [<a class="bk_pop" href="#lgmd2a.REF.din_er.1997.222">Din&#x000e7;er et al 1997</a>, <a class="bk_pop" href="#lgmd2a.REF.pogoda.2000.295">Pogoda et al 2000</a>, <a class="bk_pop" href="#lgmd2a.REF.cankiklain.2004.152">Canki-Klain et al 2004</a>, <a class="bk_pop" href="#lgmd2a.REF.chrob_kov_.2004.659">Chrob&#x000e1;kov&#x000e1; et al 2004</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2005.218">Fanin et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.milic.2005.657">Milic &#x00026; Canki-Klain 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.balci.2006.293">Balci et al 2006</a>, <a class="bk_pop" href="#lgmd2a.REF.hanisch.2007.157">Hanisch et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.todorova.2007.225">Todorova et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.stehl_kov_.2014.154">Stehl&#x000ed;kov&#x000e1; et al 2014</a>, <a class="bk_pop" href="#lgmd2a.REF.dorobek.2015.637">Dorobek et al 2015</a>]. This <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may have originated in the eastern Mediterranean region [<a class="bk_pop" href="#lgmd2a.REF.hermanov_.2006.424">Hermanov&#x000e1; et al 2006</a>].</div></li><li class="half_rhythm"><div>Guipuzcoa province in the Basque country of Spain, and in Brazil (c.2362_2363delAGinsTCATCT) [<a class="bk_pop" href="#lgmd2a.REF.urtasun.1998.1735">Urtasun et al 1998</a>, <a class="bk_pop" href="#lgmd2a.REF.de_paula.2002.825">de Paula et al 2002</a>]</div></li><li class="half_rhythm"><div>Japan (c.1795_1796insA) [<a class="bk_pop" href="#lgmd2a.REF.kawai.1998.1493">Kawai et al 1998</a>, <a class="bk_pop" href="#lgmd2a.REF.chae.2001.547">Chae et al 2001</a>]</div></li><li class="half_rhythm"><div>Chioggia village in the Venetian lagoon of Italy (p.Arg490Gln) [<a class="bk_pop" href="#lgmd2a.REF.fanin.2005.218">Fanin et al 2005</a>]</div></li><li class="half_rhythm"><div>M&#x000f2;cheni community in the Fersina River valley in the Italian Alps (c.1193+6T&#x0003e;A) [<a class="bk_pop" href="#lgmd2a.REF.fanin.2012.601">Fanin et al 2012</a>]</div></li><li class="half_rhythm"><div>Agarwal community in northern India (p.Asp780His, c.2099-1G&#x0003e;T, c.2051-1G&#x0003e;T) [<a class="bk_pop" href="#lgmd2a.REF.ankala.2013.931">Ankala et al 2013</a>, <a class="bk_pop" href="#lgmd2a.REF.khadilkar.2016.108">Khadilkar et al 2016</a>]</div></li><li class="half_rhythm"><div>Northern European countries including UK, Norway, Sweden, Denmark (dominantly inherited c.643_663del21) [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>]</div></li><li class="half_rhythm"><div>Tlaxcala village in central Mexico (p.Ala116Asp) [<a class="bk_pop" href="#lgmd2a.REF.pantojamelendez.2017.e0170280">Pantoja-Melendez et al 2017</a>]</div></li></ul><p>For more information, see <a href="/books/NBK1313/#lgmd2a.molgen.TA">Table A</a>.</p><div id="lgmd2a.T.selected_capn3_pathogenic_varia" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>CAPN3</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1313/table/lgmd2a.T.selected_capn3_pathogenic_varia/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__lgmd2a.T.selected_capn3_pathogenic_varia_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_3" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.133G&#x0003e;A</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Ala45Thr</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_3" rowspan="14" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000070.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000070<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_000061.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000061<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.347C&#x0003e;A&#x000a0;<sup>2</sup></td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Ala116Asp</td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.550delA</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Thr184ArgfsTer33</td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.643_663del21</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Ser215_Gly221del</td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.946-1G&#x0003e;A<br />(IVS6-1G&#x0003e;A)</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.1193+6T&#x0003e;A</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.1265A&#x0003e;G</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Asp419Gly</td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.1466G&#x0003e;A</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Arg489Gln</td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.1795_1796insA</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Thr599AsnfsTer30</td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.2051-1G&#x0003e;T</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="col" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.2099-1G&#x0003e;T</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.2306G&#x0003e;A</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Arg769Gln</td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.2338G&#x0003e;C</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Asp780His</td></tr><tr><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">c.2362_2363delAGinsTCATCT<br />(2362AG&#x0003e;TCATCT)</td><td headers="hd_h_lgmd2a.T.selected_capn3_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="background-color:rgb(255,255,255);text-align:left;vertical-align:middle;">p.Arg788SerfsTer13</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="lgmd2a.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="lgmd2a.TF.2.2"><p class="no_margin">This variant was reported as c.348C&#x0003e;A; however, based on the sequencing trace in <a class="bk_pop" href="#lgmd2a.REF.pantojamelendez.2017.e0170280">Pantoja-Melendez et al [2017]</a> the correct naming of this variant is c.347C&#x0003e;A.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Calpain-3 is an enzymatic protein of approximately 94 kd molecular weight (also called p94) composed of 821 amino acids. It is the muscle-specific member of a family of Ca<sup>++</sup>-activated neutral proteases, which cleave proteins into short polypeptides. Calpain-3 is a multidomain protein with three exclusive sequence inserts (NS, IS1, IS2) [<a class="bk_pop" href="#lgmd2a.REF.ono.1998.17073">Ono et al 1998</a>]:</p><ul><li class="half_rhythm"><div>Domain I. Regulatory role</div></li><li class="half_rhythm"><div>Domain II. Proteolytic module</div></li><li class="half_rhythm"><div>Domain III. C2-like <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a></div></li><li class="half_rhythm"><div>Domain IV. Binds Ca<sup>++</sup> ions [<a class="bk_pop" href="#lgmd2a.REF.ono.1998.17073">Ono et al 1998</a>].</div></li><li class="half_rhythm"><div>Sequence NS. Unknown function [<a class="bk_pop" href="#lgmd2a.REF.sorimachi.2001.653">Sorimachi &#x00026; Suzuki 2001</a>]</div></li><li class="half_rhythm"><div>Sequence IS1. Three autocatalytic sites [<a class="bk_pop" href="#lgmd2a.REF.kinbara.1998.415">Kinbara et al 1998</a>]</div></li><li class="half_rhythm"><div>Sequence IS2. Contains a nuclear <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> signal, suggesting that calpain-3 may have a function in the nucleus, processing transcription factors.</div></li></ul><p>Calpain-3 is expressed predominantly in skeletal muscle. Upon stimulation, calpain-3 both activates and inactivates itself rapidly through autocatalysis. In the sarcomeres, calpain-3 directly binds to titin [<a class="bk_pop" href="#lgmd2a.REF.keira.2003.659">Keira et al 2003</a>] and changes its localization from the M-lines to the NA2 regions as the sarcomeres extend. Calpain-3 is thought to process proteins involved in signaling pathways, transcription factors, calcium transport, and cytoskeletal proteins as part of a process called sarcomere remodeling, in which the synthesis of novel proteins is balanced by the degradation of misfolded proteins [<a class="bk_pop" href="#lgmd2a.REF.baghdiguian.1999.503">Baghdiguian et al 1999</a>, <a class="bk_pop" href="#lgmd2a.REF.baghdiguian.2001.254">Baghdiguian et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.kramerova.2005.2125">Kramerova et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.duguez.2006.3427">Duguez et al 2006</a>, <a class="bk_pop" href="#lgmd2a.REF.kramerova.2007.128">Kramerova et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.beckmann.2008.913">Beckmann &#x00026; Spencer 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.benayoun.2008.1521">Benayoun et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.kramerova.2008.3271">Kramerova et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.s_enz.2008.e3750">S&#x000e1;enz et al 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2009c.383">Fanin et al 2009c</a>, <a class="bk_pop" href="#lgmd2a.REF.ono.2010.22986">Ono et al 2010</a>, <a class="bk_pop" href="#lgmd2a.REF.ermolova.2011.3331">Ermolova et al 2011</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The majority of <i>CAPN3</i> pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants and result in recessive disease. Most individuals with calpainopathy have complete or partial calpain-3 protein deficiency on muscle biopsy. In 10%-30% of individuals with calpainopathy, muscle biopsy shows a normal amount of protein [<a class="bk_pop" href="#lgmd2a.REF.talim.2001.692">Talim et al 2001</a>, <a class="bk_pop" href="#lgmd2a.REF.de_paula.2002.825">de Paula et al 2002</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2004.52">Fanin et al 2004</a>, <a class="bk_pop" href="#lgmd2a.REF.groen.2007.3237">Groen et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.milic.2007.148">Milic et al 2007</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2009b.598">Fanin et al 2009b</a>] even though calpain-3 may have lost its autocatalytic activity and may be functionally inactive [<a class="bk_pop" href="#lgmd2a.REF.fanin.2003.1929">Fanin et al 2003</a>, <a class="bk_pop" href="#lgmd2a.REF.fanin.2007b.38">Fanin et al 2007b</a>].</p><p>The mobility of calpain-3 between the sarcomeric M-lines and the cytosol may have a key role in physical stress, and it is compromised in calpainopathy when its protease activity has been lost. An impairment of calpain proteolytic activity results in sarcomere remodeling by promoting ubiquitin-mediated degradation of sarcomeric proteins [<a class="bk_pop" href="#lgmd2a.REF.duguez.2006.3427">Duguez et al 2006</a>]. This degradation process may depend on ubiquitous calpains in the initial stage, and on the UPS in the later stages [<a class="bk_pop" href="#lgmd2a.REF.kramerova.2005.2125">Kramerova et al 2005</a>, <a class="bk_pop" href="#lgmd2a.REF.beckmann.2008.913">Beckmann &#x00026; Spencer 2008</a>, <a class="bk_pop" href="#lgmd2a.REF.rajakumar.2013.2009">Rajakumar et al 2013</a>]. Impaired sarcomere remodeling would also affect myoblast fusion and repair, as well as the regenerative capacity of muscle in calpainopathy. The activation of the muscle atrophy process appears to depend mainly on the induction of the ubiquitin-proteasome system [<a class="bk_pop" href="#lgmd2a.REF.fanin.2013.762">Fanin et al 2013</a>].</p><p>The mechanism by which <i>CAPN3</i> pathogenic variants result in a dominant disease has been proposed to be a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect [<a class="bk_pop" href="#lgmd2a.REF.vissing.2016.2154">Vissing et al 2016</a>]. Since the active calpain-3 is a homodimer, the aberrant protein could polymerize with the wild type protein and render the complex inactive.</p></div><div id="lgmd2a.References"><h2 id="_lgmd2a_References_">References</h2><div id="lgmd2a.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.anderson.1998.1169">Anderson LV, Davison K, Moss JA, Richard I, Fardeau M, Tome FM, Hubner C, Lasa A, Colomer J, Beckmann JS. Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A. <span><span class="ref-journal">Am J Pathol. </span>1998;<span class="ref-vol">153</span>:1169–79.</span> [<a href="/pmc/articles/PMC1853046/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1853046</span></a>] [<a href="/pubmed/9777948" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9777948</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.anderson.2000.553">Anderson LV, Harrison RM, Pogue R, Vafiadaki E, Pollitt C, Davison K, Moss JA, Keers S, Pyle A, Shaw PJ, Mahjneh I, Argov Z, Greenberg CR, Wrogemann K, Bertorini T, Goebel HH, Beckmann JS, Bashir R, Bushby KM. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). <span><span class="ref-journal">Neuromusc Disord. </span>2000;<span class="ref-vol">10</span>:553–9.</span> [<a href="/pubmed/11053681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11053681</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.anderson.1999.1017">Anderson LVB, Davison K. Multiplex western blotting system for the analysis of muscular dystrophy proteins. <span><span class="ref-journal">Am J Pathol. </span>1999;<span class="ref-vol">154</span>:1017–22.</span> [<a href="/pmc/articles/PMC1866550/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1866550</span></a>] [<a href="/pubmed/10233840" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10233840</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.angelini.2010.41">Angelini C, Nardetto L, Borsato C, Padoan R, Fanin M, Nascimbeni AC, Tasca E. The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). <span><span class="ref-journal">Neurol Res. </span>2010;<span class="ref-vol">32</span>:41–6.</span> [<a href="/pubmed/20092694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20092694</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.ankala.2013.931">Ankala A, Kohn JN, Dastur R, Gaitonde P, Khadilkar SV, Hegde MR. Ancestral founder mutations in calpain-3 in the Indian Agarwal community: historical, clinical, and molecular perspective. <span><span class="ref-journal">Muscle Nerve. </span>2013;<span class="ref-vol">47</span>:931–7.</span> [<a href="/pubmed/23666804" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23666804</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.arikawa.1991.1491">Arikawa E, Hoffman EP, Kaido M, Nonaka I, Sugita H, Arahata K. The frequency of patients with dystrophin abnormalities in a limb-girdle patient population. <span><span class="ref-journal">Neurology. </span>1991;<span class="ref-vol">41</span>:1491–6.</span> [<a href="/pubmed/1842672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1842672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.awater.2012.153">Awater C, Zerres K, Rudnik-Sch&#x000f6;neborn S. Pregnancy course and outcome in women with hereditary neuromuscular disorders: comparison of obstetric risks in 178 patients. <span><span class="ref-journal">Eur J Obstet Gynecol Reprod Biol. </span>2012;<span class="ref-vol">162</span>:153–9.</span> [<a href="/pubmed/22459654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22459654</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.baghdiguian.1999.503">Baghdiguian S, Martin M, Richard I, Pons F, Astier C, Bourg N, Hay RT, Chemaly R, Halaby G, Loiselet J, Anderson LV, Lopez de Munain A, Fardeau M, Mangeat P, Beckmann JS, Lefranc G. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. <span><span class="ref-journal">Nat Med. </span>1999;<span class="ref-vol">5</span>:503–11.</span> [<a href="/pubmed/10229226" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10229226</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.baghdiguian.2001.254">Baghdiguian S, Richard I, Martin M, Coopman P, Beckmann JS, Mangeat P, Lefranc G. Pathophysiology of limb girdle muscular dystrophy type 2A: hypothesis and new insights into the IkappaB alpha/NF-kappaB survival pathway in skeletal muscle. <span><span class="ref-journal">J Mol Med. </span>2001;<span class="ref-vol">79</span>:254–61.</span> [<a href="/pubmed/11485017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11485017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.balci.2006.293">Balci B, Aurino S, Haliloglu G, Talim B, Erdem S, Akcoren Z, Tan E, Caglar M, Richard I, Nigro V, Topalo&#x0011f;lu H, Din&#x000e7;er P. Calpain-3 mutations in Turkey. <span><span class="ref-journal">Eur J Pediatr. </span>2006;<span class="ref-vol">165</span>:293–8.</span> [<a href="/pubmed/16411092" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16411092</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.bartoli.2012.99">Bartoli M, Negre P, Wein N, Bourgeois P, Pecheux C, Levy N, Krahn M. Validation of comparative genomic hybridization arrays for the detection of genomic rearrangements of the calpain-3 and dysferlin genes. <span><span class="ref-journal">Clin Genet. </span>2012;<span class="ref-vol">81</span>:99–101.</span> [<a href="/pubmed/22150418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22150418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.beckmann.1991.141">Beckmann JS, Richard I, Hillaire D, Broux O, Antignac C, Bois E, Cann H, Cottingham RW Jr, Feingold N, Feingold J, et al.  A gene for limb-girdle muscular dystrophy maps to chromosome 15 by linkage. <span><span class="ref-journal">C R Acad Sci III. </span>1991;<span class="ref-vol">312</span>:141–8.</span> [<a href="/pubmed/1901754" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1901754</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.beckmann.2008.913">Beckmann JS, Spencer M. Calpain 3, the "gatekeeper" of proper sarcomere assembly, turnover and maintenance. <span><span class="ref-journal">Neuromusc Disord. </span>2008;<span class="ref-vol">18</span>:913–21.</span> [<a href="/pmc/articles/PMC2614824/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2614824</span></a>] [<a href="/pubmed/18974005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18974005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.benayoun.2008.1521">Benayoun B, Baghdiguian S, Lajmanovich A, Bartoli M, Daniele N, Gicquel E, Bourg N, Raynaud F, Pasquier MA, Suel L, Lochmuller H, Lefranc G, Richard I. NF-kB-dependent expression of the antiapoptotic factor c-FLIP is regulated by calpain 3, the protein involved in limb-girdle muscular dystrophy type 2A. <span><span class="ref-journal">FASEB J. </span>2008;<span class="ref-vol">22</span>:1521–9.</span> [<a href="/pubmed/18073330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18073330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.bl_zquez.2013.1387">Bl&#x000e1;zquez L, Aiastui A, Goicoechea M, Martins de Araujo M, Avril A, Beley C, Garc&#x000ed;a L, Valc&#x000e1;rcel J, Fortes P, L&#x000f3;pez de Munain A. In vitro correction of a pseudoexon-generating deep intronic mutation in LGMD2A by antisense oligonucleotides and modified small nuclear RNAs. <span><span class="ref-journal">Hum Mutat. </span>2013;<span class="ref-vol">34</span>:1387–95.</span> [<a href="/pubmed/23864287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23864287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.bl_zquez.2008.173">Bl&#x000e1;zquez L, Azpitarte M, S&#x000e1;enz A, Goicoechea M, Otaegui D, Ferrer X, Illa I, Gutierrez-Rivas E, Vilchez JJ, L&#x000f3;pez de Munain A. Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis. <span><span class="ref-journal">Neurogenetics. </span>2008;<span class="ref-vol">9</span>:173–82.</span> [<a href="/pubmed/18563459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18563459</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.borsato.2006.17">Borsato C, Padoan R, Stramare R, Fanin M, Angelini C. Limb-girdle muscular dystrophies type 2A and 2B: clinical and radiological aspects. <span><span class="ref-journal">Basic Appl Myol. </span>2006;<span class="ref-vol">16</span>:17–25.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.brown.2006.875">Brown RH Jr, Amato A. Calpainopathy and eosinophilic myositis. <span><span class="ref-journal">Ann Neurol. </span>2006;<span class="ref-vol">59</span>:875–7.</span> [<a href="/pubmed/16718709" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16718709</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.burke.2010.407">Burke G, Hillier C, Cole J, Sampson M, Bridges L, Bushby K, Barresi R, Hammans SR. Calpainopathy presenting as foot drop in a 41 year old. <span><span class="ref-journal">Neuromusc Disord. </span>2010;<span class="ref-vol">20</span>:407–10.</span> [<a href="/pubmed/20580976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20580976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.bushby.2009.314">Bushby K. Diagnosis and management of the limb girdle muscular dystrophies. <span><span class="ref-journal">Pract Neurol. </span>2009;<span class="ref-vol">9</span>:314–23.</span> [<a href="/pubmed/19923111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19923111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.bushby.1999.1403">Bushby KM. Making sense of the limb-girdle muscular dystrophies. <span><span class="ref-journal">Brain. </span>1999;<span class="ref-vol">122</span>:1403–20.</span> [<a href="/pubmed/10430828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10430828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.bushby.2003">Bushby KM, Beckmann JS (2003) The 105th ENMC sponsored workshop: pathogenesis in the non-sarcoglycan limb-girdle muscular dystrophies, Naarden, April 12-14, 2002. Neuromusc Disord 13:80-90. [<a href="/pubmed/12467737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12467737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.cankiklain.2004.152">Canki-Klain N, Milic A, Kovac B, Trlaja A, Grgicevic D, Zurak N, Fardeau M, Leturcq F, Kaplan JC, Urtizberea JA, Politano L, Piluso G, Feingold J. Prevalence of the 550delA mutation in calpainopathy (LGMD 2A) in Croatia. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">125A</span>:152–6.</span> [<a href="/pubmed/14981715" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14981715</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.chae.2001.547">Chae J, Minami N, Jin Y, Nakagawa M, Murayama K, Igarashi F, Nonaka I. Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy. <span><span class="ref-journal">Neuromusc Disord. </span>2001;<span class="ref-vol">11</span>:547–55.</span> [<a href="/pubmed/11525884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11525884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.chou.1999.1015">Chou FL, Angelini C, Daentl D, Garcia C, Greco C, Hausmanowa-Petrusewicz I, Fidzianska A, Wessel H, Hoffman EP. Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population. <span><span class="ref-journal">Neurology. </span>1999;<span class="ref-vol">52</span>:1015–20.</span> [<a href="/pubmed/10102422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10102422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.chrob_kov_.2004.659">Chrob&#x000e1;kov&#x000e1; T, Hermanov&#x000e1; M, Kroupov&#x000e1; I, Vondr&#x000e1;cek P, Mar&#x000ed;kov&#x000e1; T, Mazanec R, Z&#x000e1;mecn&#x000ed;k J, Stanek J, Havlov&#x000e1; M, Fajkusov&#x000e1; L. Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome. <span><span class="ref-journal">Neuromusc Disord. </span>2004;<span class="ref-vol">14</span>:659–65.</span> [<a href="/pubmed/15351423" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15351423</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.dadali.2010.79">Dadali EL, Shagina OA, Ryzhkova OP, Rudenskaia GE, Fedotov VP, Poliakov AV. Clinical-genetic characteristics of limb girdle-muscular dystrophy type 2A. <span><span class="ref-journal">Zh Nevrol Psikhiatr Im S S Korsakova. </span>2010;<span class="ref-vol">110</span>:79–83.</span> [<a href="/pubmed/20517216" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20517216</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.dangelo.2011.54">D'Angelo MG, Romei M, Lo Mauro A, Marchi E, Gandossini S, Bonato S, Comi GP, Magri F, Turconi AC, Pedotti A, Bresolin N, Aliverti A. Respiratory pattern in an adult population of dystrophic patients. <span><span class="ref-journal">J Neurol Sci. </span>2011;<span class="ref-vol">306</span>:54–61.</span> [<a href="/pubmed/21529845" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21529845</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.degardin.2010.1219">Degardin A, Morillon D, Lacour A, Cotten A, Vermersch P, Stojkovic T. Morphologic imaging in muscular dystrophies and inflammatory myopathies. <span><span class="ref-journal">Skeletal Radiol. </span>2010;<span class="ref-vol">39</span>:1219–27.</span> [<a href="/pubmed/20449587" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20449587</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.de_paula.2002.825">de Paula F, Vainzof M, Passos-Bueno MR, de C&#x000e1;ssia M, Pavanello R, Matioli SR, Anderson L, Nigro V, Zatz M. Clinical variability in calpainopathy: what makes the difference? <span><span class="ref-journal">Eur J Hum Genet. </span>2002;<span class="ref-vol">10</span>:825–32.</span> [<a href="/pubmed/12461690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12461690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.de_tullio.2003.689">De Tullio R, Stifanese R, Salamino F, Pontremoli S, Melloni E. Characterization of a new p94-like calpain form in human lymphocytes. <span><span class="ref-journal">Biochem J. </span>2003;<span class="ref-vol">375</span>:689–96.</span> [<a href="/pmc/articles/PMC1223710/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1223710</span></a>] [<a href="/pubmed/12882647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12882647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.d_azmanera.2015.95">D&#x000ed;az-Manera J, Llauger J, Gallardo E, Illa I. Muscle MRI in muscular dystrophies. <span><span class="ref-journal">Acta Myol. </span>2015;<span class="ref-vol">34</span>:95–108.</span> [<a href="/pmc/articles/PMC4859076/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4859076</span></a>] [<a href="/pubmed/27199536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27199536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.din_er.1997.222">Din&#x000e7;er P, Leturcq F, Richard I, Piccolo F, Yalnizoglu D, de Toma C, Ak&#x000e7;&#x000f6;ren Z, Broux O, Deburgrave N, Brenguier L, Roudaut C, Urtizberea JA, Jung D, Tan E, Jeanpierre M, Campbell KP, Kaplan JC, Beckmann JS, Topalo&#x0011f;lu H. A biochemical, genetic, and clinical survey of autosomal recessive limb girdle muscular dystrophies in Turkey. <span><span class="ref-journal">Ann Neurol. </span>1997;<span class="ref-vol">42</span>:222–9.</span> [<a href="/pubmed/9266733" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9266733</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.dirik.2001.235">Dirik E, Aydin A, Kurul S, Sahin B. Limb girdle muscular dystrophy type 2A presenting with cardiac arrest. <span><span class="ref-journal">Pediatr Neurol. </span>2001;<span class="ref-vol">24</span>:235–7.</span> [<a href="/pubmed/11301229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11301229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.dorobek.2015.637">Dorobek M, Ryniewicz B, Kabzinska D, Fidzianska A, Styczynska M, Hausmanowa-Petrusewicz I. The frequency of c.550delA mutation of the CAPN3 gene in the Polish LGMD2A population. <span><span class="ref-journal">Genet Test Mol Biomarkers. </span>2015;<span class="ref-vol">19</span>:637–40.</span> [<a href="/pubmed/26484845" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26484845</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.duguez.2006.3427">Duguez S, Bartoli M, Richard I. Calpain 3: a key regulator of the sarcomere? <span><span class="ref-journal">FEBS J. </span>2006;<span class="ref-vol">273</span>:3427–36.</span> [<a href="/pubmed/16884488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16884488</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.duno.2008.935">Duno M, Sveen ML, Schwartz M, Vissing J. cDNA analyses of CAPN3 enhance mutation detection and reveal a low prevalence of LGMD2A patients in Denmark. <span><span class="ref-journal">Eur J Hum Genet. </span>2008;<span class="ref-vol">16</span>:935–40.</span> [<a href="/pubmed/18337726" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18337726</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.eagle.2002.975">Eagle M. Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases. Newcastle, January 2002. <span><span class="ref-journal">Neuromusc Disord. </span>2002;<span class="ref-vol">12</span>:975–83.</span> [<a href="/pubmed/12467755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12467755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.eggers.1998.4">Eggers S, Zatz M. Social adjustment in adult males affected with progressive muscular dystrophy. <span><span class="ref-journal">Am J Med Genet. </span>1998;<span class="ref-vol">81</span>:4–12.</span> [<a href="/pubmed/9514580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9514580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.ermolova.2011.3331">Ermolova N, Kudryashova E, DiFranco M, Vergara J, Kramerova I, Spencer MJ. Pathogenity of some limb girdle muscular dystrophy mutations can result from reduced anchorage to myofibrils and altered stability of calpain 3. <span><span class="ref-journal">Hum Mol Genet. </span>2011;<span class="ref-vol">20</span>:3331–45.</span> [<a href="/pmc/articles/PMC3153300/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3153300</span></a>] [<a href="/pubmed/21624972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21624972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fadaee.2016.277">Fadaee M, Kariminejad A, Fattahi Z, Nafissi S, Reza Godarzi H, Beheshtian M, Vazehan R, Reza Akbari M, Kahrizi K, Najmabadi H. report of limb girdle muscular dystrophy type 2A in six Iranian patients, one with a novel deletion in CAPN3 gene. <span><span class="ref-journal">Neuromusc Disord. </span>2016;<span class="ref-vol">26</span>:277–82.</span> [<a href="/pubmed/27020652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27020652</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2015.163">Fanin M, Angelini C. Protein and genetic diagnosis of limb girdle muscular dystrophy type 2A: the yield and the pitfalls. <span><span class="ref-journal">Muscle Nerve. </span>2015;<span class="ref-vol">52</span>:163–73.</span> [<a href="/pubmed/25900067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25900067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2012.601">Fanin M, Benedicenti F, Fritegotto C, Nascimbeni A, Peterle E, Stanzial F, Cristofoletti A, Castellan C, Angelini C. An intronic mutation causes severe LGMD2A in a large inbred family belonging to a genetic isolate in the Alps. <span><span class="ref-journal">Clin Genet. </span>2012;<span class="ref-vol">82</span>:601–2.</span> [<a href="/pubmed/22486197" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22486197</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2004.52">Fanin M, Fulizio L, Nascimbeni AC, Spinazzi M, Piluso G, Ventriglia VM, Ruzza G, Siciliano G, Trevisan CP, Politano L, Nigro V, Angelini C. Molecular diagnosis in LGMD2A: mutation analysis or protein testing? <span><span class="ref-journal">Hum Mutat. </span>2004;<span class="ref-vol">24</span>:52–62.</span> [<a href="/pubmed/15221789" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15221789</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2007a.609">Fanin M, Nardetto L, Nascimbeni AC, Tasca E, Spinazzi M, Padoan R, Angelini C. Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A. <span><span class="ref-journal">J Med Genet. </span>2007a;<span class="ref-vol">44</span>:609–14.</span> [<a href="/pmc/articles/PMC2597960/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2597960</span></a>] [<a href="/pubmed/17526799" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17526799</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2007b.38">Fanin M, Nascimbeni AC, Angelini C. Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations. <span><span class="ref-journal">J Med Genet. </span>2007b;<span class="ref-vol">44</span>:38–43.</span> [<a href="/pmc/articles/PMC2597906/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2597906</span></a>] [<a href="/pubmed/16971480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16971480</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2014.179">Fanin M, Nascimbeni AC, Angelini C. Gender difference in limb-girdle muscular dystrophy: a muscle fiber morphometric study in 101 patients. <span><span class="ref-journal">Clin Neuropathol. </span>2014;<span class="ref-vol">33</span>:179–85.</span> [<a href="/pubmed/24618072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24618072</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2013.762">Fanin M, Nascimbeni AC, Angelini C. Muscle atrophy in limb girdle muscular dystrophy 2A: a morphometric and molecular study. <span><span class="ref-journal">Neuropathol Appl Neurobiol. </span>2013;<span class="ref-vol">39</span>:762–71.</span> [<a href="/pubmed/23414389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23414389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2009a.1432">Fanin M, Nascimbeni AC, Aurino S, Tasca E, Pegoraro E, Nigro V, Angelini C. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. <span><span class="ref-journal">Neurology. </span>2009a;<span class="ref-vol">72</span>:1432–5.</span> [<a href="/pubmed/19380703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19380703</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2005.218">Fanin M, Nascimbeni AC, Fulizio L, Angelini C. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. <span><span class="ref-journal">Neuromusc Disord. </span>2005;<span class="ref-vol">15</span>:218–24.</span> [<a href="/pubmed/15725583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15725583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2003.1929">Fanin M, Nascimbeni AC, Fulizio L, Trevisan CP, Meznaric-Petrusa M, Angelini C. Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. <span><span class="ref-journal">Am J Pathol. </span>2003;<span class="ref-vol">163</span>:1929–36.</span> [<a href="/pmc/articles/PMC1892408/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1892408</span></a>] [<a href="/pubmed/14578192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14578192</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2009b.598">Fanin M, Nascimbeni AC, Tasca E, Angelini C. How to tackle the diagnosis of limb-girdle muscular dystrophy 2A. <span><span class="ref-journal">Eur J Hum Genet. </span>2009b;<span class="ref-vol">17</span>:598–603.</span> [<a href="/pmc/articles/PMC2986267/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2986267</span></a>] [<a href="/pubmed/18854869" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18854869</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2001.660">Fanin M, Pegoraro E, Matsuda-Asada C, Brown RH Jr, Angelini C. Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:660–5.</span> [<a href="/pubmed/11245721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11245721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fanin.2009c.383">Fanin M, Tasca E, Nascimbeni AC, Angelini C. Sarcolemmal neuronal nitric oxide synthase defect in limb girdle muscular dystrophy: an adverse modulating factor in the disease course? <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2009c;<span class="ref-vol">68</span>:383–90.</span> [<a href="/pubmed/19287313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19287313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fardeau.1996.295">Fardeau M, Hillaire D, Mignard C, Feingold N, Feingold J, Mignard D, de Ubeda B, Collin H, Tome FM, Richard I, Beckmann J. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. <span><span class="ref-journal">Brain. </span>1996;<span class="ref-vol">119</span>:295–308.</span> [<a href="/pubmed/8624690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8624690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fattahi.2017.386">Fattahi Z, Kalhor Z, Fadaee M, et al.  Improved diagnostic yield of neuromuscular disorders applying clinical exome sequencing in patients arising from a consanguineous population. <span><span class="ref-journal">Clin Genet. </span>2017;<span class="ref-vol">91</span>:386–402.</span> [<a href="/pubmed/27234031" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27234031</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.fischer.2005.538">Fischer D, Walter MC, Kesper K, Petersen JA, Aurino S, Nigro V, Kubisch C, Meindl T, Lochm&#x000fc;ller H, Wilhelm K, Urbach H, Schr&#x000f6;der R. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. <span><span class="ref-journal">J Neurol. </span>2005;<span class="ref-vol">252</span>:538–47.</span> [<a href="/pubmed/15726252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15726252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.gallardo.2011.97">Gallardo E, S&#x000e1;enz A, Illa I. Limb-girdle muscular dystrophy 2A. <span><span class="ref-journal">Handb Clin Neurol. </span>2011;<span class="ref-vol">101</span>:97–110.</span> [<a href="/pubmed/21496626" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21496626</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.georgieva.2005.399">Georgieva B, Todorova A, Kremensky I, Tournev I, Mines V, Plageras P. 550delA mutation in the calpain 3 (CAPN3) gene: DMD/BMD, SMA, or LGMD2A clinically misdiagnosed cases. <span><span class="ref-journal">Am J Med Genet. </span>2005;<span class="ref-vol">136A</span>:399–400.</span> [<a href="/pubmed/16001438" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16001438</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.ghaoui.2015.1424">Ghaoui R, Cooper ST, Lek M, Jones K, Corbett A, Reddel SW, Needham M, Liang C, Waddell LB, Nicholson G, O&#x02019;Grady G, Kaur S, Ong R, Davis M, Sue CM, Liang NG, North KN, MacArthur DG, Clarke NF. Use of whole-exome sequencing for diagnosis of limb-girdle muscular dystrophy. Outcomes and lessons learned. <span><span class="ref-journal">JAMA Neurol. </span>2015;<span class="ref-vol">72</span>:1424–32.</span> [<a href="/pubmed/26436962" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26436962</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.ginjaar.2008.816a">Ginjaar I, Tuit S, Frankhuizen W, van der Kooi A, Doorn P, Sival D, Bakker E. MLPA analysis of the CAPN3 gene detects large deletions in LGMD2A patients. <span><span class="ref-journal">Neuromuscul Disord. </span>2008;<span class="ref-vol">18</span>:816A.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.g_mezd_az.2012.338">G&#x000f3;mez-D&#x000ed;az B, Rosas-Vargas H, Roque-Ramirez B, Meza-Espinoza P, Ruano-Calderon LA, Fernandez-Valverde F, Escalante-Bautista D, Escobar-Cedillo RE, Sanchez-Chapul L, Vargas-Canas S, Lopez-Hernandez LB, Bahena-Martinez E, Luna-Angulo AB, Canto P, Coral-Vazquez RM. Immunodetection analysis of muscular dystrophies in Mexico. <span><span class="ref-journal">Muscle Nerve. </span>2012;<span class="ref-vol">45</span>:338–45.</span> [<a href="/pubmed/22334167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22334167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.groen.2007.3237">Groen EJ, Charlton R, Barresi R, Anderson LV, Eagle M, Hudson J, Koref MS, Straub V, Bushby KMD. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy. <span><span class="ref-journal">Brain. </span>2007;<span class="ref-vol">130</span>:3237–49.</span> [<a href="/pubmed/18055493" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18055493</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.guglieri.2008.258">Guglieri M, Magri F, D'Angelo MG, Prelle A, Morandi L, Rodolico C, Cagliani R, Mora M, Fortunato F, Bordoni A, Del Bo R, Ghezzi S, Pagliarani S, Lucchiari S, Salani S, Zecca C, Lamperti C, Ronchi D, Aguennouz M, Ciscato P, Di Blasi C, Ruggieri A, Moroni I, Turconi A, Toscano A, Moggio M, Bresolin N, Comi GP. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. <span><span class="ref-journal">Hum Mut. </span>2008;<span class="ref-vol">29</span>:258–66.</span> [<a href="/pubmed/17994539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17994539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.hackman.2002.492">Hackman P, Vihola A, Haravuori H, Marchand S, Sarparanta J, De Seze J, Labeit S, Witt C, Peltonen L, Richard I, Udd B. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:492–500.</span> [<a href="/pmc/articles/PMC379188/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379188</span></a>] [<a href="/pubmed/12145747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12145747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.hanisch.2007.157">Hanisch F, M&#x000fc;ller CR, Grimm D, Xue L, Traufeller K, Merkenschlager A, Zierz S, Deschauer M. Frequency of calpain-3 c.550delA mutation in limb girdle muscular dystrophy type 2 and isolated hyperCKemia in German patients. <span><span class="ref-journal">Clin Neuropathol. </span>2007;<span class="ref-vol">26</span>:157–63.</span> [<a href="/pubmed/17702496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17702496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.haravuori.2001.869">Haravuori H, Vihola A, Straub V, Auranen M, Richard I, Marchand S, Voit T, Labeit S, Somer H, Peltonen L, Beckmann JS, Udd B. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: titin is the candidate gene. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:869–77.</span> [<a href="/pubmed/11294923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11294923</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.hashiguchi.2014.1097">Hashiguchi S, Adachi K, Arii Y, Kashiwagi S, Sato M, Kagawa N, Kawai H. A clinic-pathological investigation of two autopsy cases of calpainopathy (LGMD2A). <span><span class="ref-journal">Brain Nerve. </span>2014;<span class="ref-vol">66</span>:1097–102.</span> [<a href="/pubmed/25200581" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25200581</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.hauerslev.2012.43">Hauerslev S, Sveen ML, Duno M, Angelini C, Vissing J, Krag TO. Calpain 3 is important for muscle regeneration: evidence from patients with limb girdle muscular dystrophies. <span><span class="ref-journal">BMC Musculoskelet Disord. </span>2012;<span class="ref-vol">13</span>:43.</span> [<a href="/pmc/articles/PMC3338386/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3338386</span></a>] [<a href="/pubmed/22443334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22443334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.herasse.1999.4047">Herasse M, Ono Y, Fougerousse F, Kimura E, Stockholm D, Beley C, Montarras D, Pinset C, Sorimachi H, Suzuki K, Beckmann JS, Richard I. Expression and functional characteristics of calpain 3 isoforms generated through tissue-specific transcriptional and posttranscriptional events. <span><span class="ref-journal">Mol Cell Biol. </span>1999;<span class="ref-vol">19</span>:4047–55.</span> [<a href="/pmc/articles/PMC104364/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC104364</span></a>] [<a href="/pubmed/10330145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10330145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.hermanov_.2006.424">Hermanov&#x000e1; M, Zapletalov&#x000e1; E, Sedl&#x000e1;ckov&#x000e1; J, Chrob&#x000e1;kov&#x000e1; T, Letocha O, Kroupov&#x000e1; I, Z&#x000e1;mecn&#x000ed;k J, Vondr&#x000e1;cek P, Mazanec R, Mar&#x000ed;kov&#x000e1; T, Voh&#x000e1;nka S, Fajkusov&#x000e1; L. Analysis of histopathologic and molecular pathologic findings in Czech LGMD2A patients. <span><span class="ref-journal">Muscle Nerve. </span>2006;<span class="ref-vol">33</span>:424–32.</span> [<a href="/pubmed/16372320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16372320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.inashkina.2016.200">Inashkina I, Jankevics E, Stavusis J, Vasiljeva I, Viksne K, Micule I, Strautmanis J, Naudina MS, Cimbalistiene L, Kucinskas V, Krumina A, Utkus A, Burnyte B, Matuleviciene A, Lace B. Robust genotyping tool for autosomal recessive type of limb-girdle muscular dystrophies. <span><span class="ref-journal">BMC Musculoskelet Disord. </span>2016;<span class="ref-vol">17</span>:200.</span> [<a href="/pmc/articles/PMC4855345/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4855345</span></a>] [<a href="/pubmed/27142102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27142102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.jaka.2014.448">Jaka O, Azpitarte M, Paisan-Ruiz C, Zulaika M, Casas-Fraile L, Sanz R, Trevisiol N, Levy N, Bartoli M, Krahn M, Lopez de Munain A, S&#x000e1;enz A. Entire CAPN3 gene deletion in a patient with limb girdle muscular dystrophy type 2A. <span><span class="ref-journal">Muscle Nerve. </span>2014;<span class="ref-vol">50</span>:448–53.</span> [<a href="/pubmed/24715573" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24715573</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.joncourt.2003.667a">Joncourt F, Burgunder J, Steinlin M, Gallati S. LGMD2A caused by a large deletion: clinical, histochemical and molecular analysis. <span><span class="ref-journal">Eur J Hum Genet. </span>2003;<span class="ref-vol">11</span>(S1):667A.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kana.2014.278">Kana V, Kellenberger CJ, Klein A. Muscle magnetic resonance imaging of the lower limbs: valuable diagnostic tool in the investigation of childhood neuromuscular disorders. <span><span class="ref-journal">Neuropediatrics. </span>2014;<span class="ref-vol">45</span>:278–88.</span> [<a href="/pubmed/25025777" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25025777</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kawabata.2003.623">Kawabata Y, Hata S, Ono Y, Ito Y, Suzuki K, Abe K, Sorimachi H. Newly identified exons encoding novel variants of p94/calpain-3 are expressed ubiquitously and overlap the alpha-glucosidase C gene. <span><span class="ref-journal">FEBS Lett. </span>2003;<span class="ref-vol">555</span>:623–30.</span> [<a href="/pubmed/14675785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14675785</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kawai.1998.1493">Kawai H, Akaike M, Kunishige M, Inui T, Adachi K, Kimura C, Kawajiri M, Nishida Y, Endo I, Kashiwagi S, Nishino H, Fujiwara T, Okuno S, Roudaut C, Richard I, Beckmann JS, Miyoshi K, Matsumoto T. Clinical, pathological, and genetic features of limb-girdle muscular dystrophy type 2A with new calpain 3 gene mutations in seven patients from three Japanese families. <span><span class="ref-journal">Muscle Nerve. </span>1998;<span class="ref-vol">21</span>:1493–501.</span> [<a href="/pubmed/9771675" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9771675</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.keira.2007.513">Keira Y, Noguchi S, Kurokawa R, Fujita M, Minami N, Hayashi YK, Kato T, Nishino I. Characterization of lobulated fibers in limb girdle muscular dystrophy type 2A by gene expression profiling. <span><span class="ref-journal">Neurosci Res. </span>2007;<span class="ref-vol">57</span>:513–21.</span> [<a href="/pubmed/17258832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17258832</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.keira.2003.659">Keira Y, Noguchi S, Minami N, Hayashi YK, Nishino I. Localization of calpain 3 in human skeletal muscle and its alteration in limb-girdle muscular dystrophy 2A muscle. <span><span class="ref-journal">J Biochem. </span>2003;<span class="ref-vol">133</span>:659–64.</span> [<a href="/pubmed/12801918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12801918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.khadilkar.2016.108">Khadilkar SV, Chaudhari CR, Dastur RS, Gaitonde PS, Yadav JG. Limb-girdle muscular dystrophy in the Agarwals: utility of founder mutations in CAPN3 gene. <span><span class="ref-journal">Ann Indian Acad Neurol. </span>2016;<span class="ref-vol">19</span>:108–11.</span> [<a href="/pmc/articles/PMC4782525/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4782525</span></a>] [<a href="/pubmed/27011640" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27011640</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kinbara.1998.415">Kinbara K, Sorimachi H, Ishiura S, Suzuki K. Skeletal muscle specific calpain, p94: structure and physiological function. <span><span class="ref-journal">Biochem Pharmacol. </span>1998;<span class="ref-vol">56</span>:415–20.</span> [<a href="/pubmed/9763216" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9763216</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.krahn.2006a.444">Krahn M, Bernard R, Pecheux C, Hammouda EH, Lopez de Munain A, Cobo AM, Romero N, Urtizberea A, Leturcq F, Levy N. Screening of the CAPN3 gene in patients with possible LGMD2A. <span><span class="ref-journal">Clin Genet. </span>2006a;<span class="ref-vol">69</span>:444–9.</span> [<a href="/pubmed/16650086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16650086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.krahn.2011.398">Krahn M, Goicoechea M, Hanisch F, Groen E, Bartoli M, P&#x000e9;cheux C, Garcia-Bragado F, Leturcq F, Jeannet PY, Lobrinus JA, Jacquemont S, Strober J, Urtizberea JA, S&#x000e1;enz A, Bushby K, L&#x000e9;vy N, Lopez de Munain A. Eosinophilic infiltration related to CAPN3 mutations: a pathophysiological component of primary calpainopathy? <span><span class="ref-journal">Clin Genet. </span>2011;<span class="ref-vol">80</span>:398–402.</span> [<a href="/pubmed/21204801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21204801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.krahn.2006b.905">Krahn M, Lopez de Munain A, Streichenberger N, Bernard R, Pecheux C, Testard H, Pena-Segura JL, Yoldi E, Cabello A, Romero NB, Poza JJ, Bouillot-Eimer S, Ferrer X, Goicoechea M, Garcia-Bragado F, Leturcq F, Urtizberea JA, Levy N. CAPN3 mutations in patients with idiopathic eosinophilic myositis. <span><span class="ref-journal">Ann Neurol. </span>2006b;<span class="ref-vol">59</span>:905–11.</span> [<a href="/pubmed/16607617" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16607617</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.krahn.2007.582">Krahn M, P&#x000e9;cheux C, Chapon F, B&#x000e9;roud C, Drouin-Garraud V, Laforet P, Romero NB, P&#x000e9;nisson-Besnier I, Bernard R, Urtizberea JA, Leturcq F, L&#x000e9;vy N. Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic deletion and evidence for messenger RNA decay. <span><span class="ref-journal">Clin Genet. </span>2007;<span class="ref-vol">72</span>:582–92.</span> [<a href="/pubmed/17979987" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17979987</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kramerova.2007.128">Kramerova I, Beckmann JS, Spencer MJ. Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A). <span><span class="ref-journal">Biochim Biophys Acta. </span>2007;<span class="ref-vol">1772</span>:128–44.</span> [<a href="/pubmed/16934440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16934440</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kramerova.2005.2125">Kramerova I, Kudryashova E, Venkatraman G, Spencer MJ. Calpain 3 participates in sarcomere remodeling by acting upstream of the ubiquitin-proteasome pathway. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:2125–34.</span> [<a href="/pubmed/15961411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15961411</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kramerova.2008.3271">Kramerova I, Kudryashova E, Wu B, Ottenheijm C, Granzier H, Spencer MJ. Novel role of calpain-3 in the triad-associated protein complex regulating calcium release in skeletal muscle. <span><span class="ref-journal">Hum Mol Genet. </span>2008;<span class="ref-vol">17</span>:3271–80.</span> [<a href="/pmc/articles/PMC2566524/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2566524</span></a>] [<a href="/pubmed/18676612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18676612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kuhn.2016.743">Kuhn M, Glaser D, Joshi PR, Zierz S, Wenninger S, Schoser B, Deschauer M. Utility of a next-generation sequencing-based gene panel investigation in German patients with genetically unclassified limb-girdle muscular dystrophy. <span><span class="ref-journal">J Neurol. </span>2016;<span class="ref-vol">263</span>:743–750.</span> [<a href="/pubmed/26886200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26886200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kyriakides.2010.767">Kyriakides T, Angelini C, Schaefer J, Sacconi S, Siciliano G, Vilchez JJ, Hilton-Jones D. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. <span><span class="ref-journal">Eur J Neurol. </span>2010;<span class="ref-vol">17</span>:767–73.</span> [<a href="/pubmed/20402744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20402744</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.lahoria.2016.29">Lahoria R, Milone M. Rhabdomyolysis featuring muscular dystrophies. <span><span class="ref-journal">J Neurol Sci. </span>2016;<span class="ref-vol">361</span>:29–33.</span> [<a href="/pubmed/26810512" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26810512</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.leidenroth.2012.999">Leidenroth A, Sorte HS, Gilfillan G, Ehrlich M, Lyle R, Hewitt JE. Diagnosis by sequencing: correction of misdiagnosis from FSHD2 to LGMD2A by whole-exome analysis. <span><span class="ref-journal">Eur J Hum Genet. </span>2012;<span class="ref-vol">20</span>:999–1003.</span> [<a href="/pmc/articles/PMC3421126/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3421126</span></a>] [<a href="/pubmed/22378277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22378277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.lo.2008.34">Lo HP, Cooper ST, Evesson FJ, Seto JT, Choitis AM, Tay V, Compton AG, Cairns AG, Corbett A, MacArthur DG, Yang N, Reardon K, North KN. Limb girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. <span><span class="ref-journal">Neuromusc Disord. </span>2008;<span class="ref-vol">18</span>:34–44.</span> [<a href="/pubmed/17897828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17897828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.luo.2011.402">Luo SS, Xi JY, Lu JH, Zhao CB, Zhu WH, Lin J, Wang Y, Ren HM, Yin B, Urtizberea AJ. Clinical and pathological features in 15 Chinese patients with calpainopathy. <span><span class="ref-journal">Muscle Nerve. </span>2011;<span class="ref-vol">43</span>:402–9.</span> [<a href="/pubmed/21321956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21321956</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.luo.2012.723">Luo SS, Xi JY, Zhu WH, Zhao CB, Lu JH, Lin J, Wang Y, Lu J, Qiao K. Genetic variability and clinical spectrum of Chinese patients with limb girdle muscular dystrophy type 2A. <span><span class="ref-journal">Muscle Nerve. </span>2012;<span class="ref-vol">46</span>:723–9.</span> [<a href="/pubmed/22926650" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22926650</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.magri.2017.55">Magri F, Nigro V, Angelini C, Mongini T, Mora M, Moroni I, et al.  The Italian limb girdle muscular dystrophy registry: relative frequency, clinical fetaures, and differential diagnosis. <span><span class="ref-journal">Muscle Nerve. </span>2017;<span class="ref-vol">55</span>:55–68.</span> [<a href="/pubmed/27184587" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27184587</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.mahmood.2013.1907">Mahmood OA, Jiang X, Zhang Q. Limb-girdle muscular dystrophy subtypes: first reported cohort from northeastern China. <span><span class="ref-journal">Neural Regen Res. </span>2013;<span class="ref-vol">8</span>:1907–18.</span> [<a href="/pmc/articles/PMC4145977/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4145977</span></a>] [<a href="/pubmed/25206500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25206500</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.matsubara.2007.819">Matsubara E, Tsuchiya A, Minami N, Nishino I, Pappolla MA, Shoji M, Abe K. A unique case of limb girdle muscular dystrophy type 2A carrying novel compound heterozygous mutations in the human CAPN3 gene. <span><span class="ref-journal">Eur J Neurol. </span>2007;<span class="ref-vol">14</span>:819–22.</span> [<a href="/pubmed/17594342" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17594342</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.mcdonald.1995.s117">McDonald CM, Johnson ER, Abresch RT, Carter GT, Fowler WM, Kilmer DD. Profiles of neuromuscular diseases. Limb-girdle syndromes. <span><span class="ref-journal">Am J Phys Med Rehabil. </span>1995;<span class="ref-vol">74</span>:S117–30.</span> [<a href="/pubmed/7576419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7576419</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.mercuri.2005.164">Mercuri E, Bushby K, Ricci E, Birchall D, Pane M, Kinali M, Allsop J, Nigro V, S&#x000e1;enz A, Nascimbeni A, Fulizio L, Angelini C, Muntoni F. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. <span><span class="ref-journal">Neuromusc Disord. </span>2005;<span class="ref-vol">15</span>:164–71.</span> [<a href="/pubmed/15694138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15694138</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.meznaricpetrusa.2002.73a">Meznaric-Petrusa MMP, Zidar J, Zupanic N, et al.  Clinical, molecular and genetic features of calpainopathy in Slovenia. <span><span class="ref-journal">Neuromuscul Disord. </span>2002;<span class="ref-vol">12</span>:73A.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.milic.2005.657">Milic A, Canki-Klain N. Calpainopathy (LGMD2A) in Croatia: molecular and haplotype analysis. <span><span class="ref-journal">Croat Med J. </span>2005;<span class="ref-vol">46</span>:657–63.</span> [<a href="/pubmed/16100770" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16100770</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.milic.2007.148">Milic A, Daniele N, Lochmuller H, Mora M, Comi GP, Moggio M, Noulet F, Walter MC, Morandi L, Poupiot J, Roudaut C, Bittner RE, Bartoli M, Richard I. A third of LGMD2A biopsies have normal calpain-3 proteolytic activity as determined by an in-vitro assay. <span><span class="ref-journal">Neuromusc Disord. </span>2007;<span class="ref-vol">17</span>:148–56.</span> [<a href="/pubmed/17236769" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17236769</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.minami.1999.31">Minami N, Nishino I, Kobayashi O, Ikezoe K, Goto Y, Nonaka I. Mutations of calpain 3 gene in patients with sporadic limb girdle muscular dystrophy in Japan. <span><span class="ref-journal">J Neurol Sci. </span>1999;<span class="ref-vol">171</span>:31–7.</span> [<a href="/pubmed/10567047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10567047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.monies.2016.32">Monies D, Alhindi HN, Almuhaizea MA, Abouelhoda M, Alazami AM, Goljan E, Alyounes B, Jaroudi D, Allssa A, Alabdulrahman K, Subhani S, El-Kalioby M, Faquih T, Wakil SM, Altassan NA, Meyer BF, Bohlega S. A first-line diagnostic assy for limb-girdle muscular dystrophy and other myopathies. <span><span class="ref-journal">Hum Genomics. </span>2016;<span class="ref-vol">10</span>:32.</span> [<a href="/pmc/articles/PMC5037890/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5037890</span></a>] [<a href="/pubmed/27671536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27671536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.moore.2006.995">Moore SA, Shilling CJ, Westra S, Wall C, Wicklund MP, Stolle C, Brown CA, Michele DE, Piccolo F, Winder TL, Stence A, Barresi R, King N, King W, Florence J, Campbell KP, Fenichel GM, Stedman HH, Kissel JT, Griggs RC, Pandya S, Mathews KD, Pestronk A, Serrano C, Darvish D, Mendell JR. Limb-girdle muscular dystrophy in the United States. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2006;<span class="ref-vol">65</span>:995–1003.</span> [<a href="/pubmed/17021404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17021404</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.moriyoshimura.2017.465">Mori-Yoshimura M, Segawa K, Minami N, Oya Y, Komaki H, Nonaka I, Nishino I, Murata M. Cardiopulmonary dysfunction in patients with limb-girdle muscular dystrophy 2A. <span><span class="ref-journal">Muscle Nerve. </span>2017;<span class="ref-vol">55</span>:465–9.</span> [<a href="/pmc/articles/PMC5396288/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5396288</span></a>] [<a href="/pubmed/27500519" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27500519</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.narayanaswami.2014.1453">Narayanaswami P, Weiss M, Selcen D, David W, Raynor E, Carter G, Wicklund M, Barohn RJ, Ensrud E, Griggs RC, Gronseth G, Amato AA. Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies. Report of the guideline development subcommittee of the American Academy of Neurology and the practical issues review panel of the American Association of Neuromuscular &#x00026; Electrodiagnostic Medicine. <span><span class="ref-journal">Neurology. </span>2014;<span class="ref-vol">83</span>:1453–63.</span> [<a href="/pmc/articles/PMC4206155/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4206155</span></a>] [<a href="/pubmed/25313375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25313375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.nascimbeni.2010.e1658">Nascimbeni AC, Fanin M, Tasca E, Angelini C. Transcriptional and translational effects of intronic CAPN3 gene mutations. <span><span class="ref-journal">Hum Mutat. </span>2010;<span class="ref-vol">31</span>:E1658–69.</span> [<a href="/pmc/articles/PMC2966865/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2966865</span></a>] [<a href="/pubmed/20635405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20635405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.nigro.2012.196">Nigro V, Piluso G. Next generation sequencing (NGS) strategies for the genetic testing of myopathies. <span><span class="ref-journal">Acta Myol. </span>2012;<span class="ref-vol">31</span>:196–200.</span> [<a href="/pmc/articles/PMC3631804/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3631804</span></a>] [<a href="/pubmed/23620651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23620651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.nigro.2014.1">Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. <span><span class="ref-journal">Acta Myol. </span>2014;<span class="ref-vol">33</span>:1–12.</span> [<a href="/pmc/articles/PMC4021627/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4021627</span></a>] [<a href="/pubmed/24843229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24843229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.norwood.2007.1305">Norwood F, de Visser M, Eymard B, Lochm&#x000fc;ller H, Bushby K. EFNS guideline on diagnosis and management of limb girdle muscular dystrophies. <span><span class="ref-journal">Eur J Neurol. </span>2007;<span class="ref-vol">14</span>:1305–12.</span> [<a href="/pubmed/18028188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18028188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.norwood.2009.3175">Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. <span><span class="ref-journal">Brain. </span>2009;<span class="ref-vol">132</span>:3175–86.</span> [<a href="/pmc/articles/PMC4038491/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4038491</span></a>] [<a href="/pubmed/19767415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19767415</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.oflazer.2009.261">Oflazer PS, Gundesli H, Zorludemir S, Sabuncu T, Din&#x000e7;er P. Eosinophilic myositis in calpainopathy: could immunosuppression of the eosinophilic myositis alter the early natural course of the dystrophic disease? <span><span class="ref-journal">Neuromusc Disord. </span>2009;<span class="ref-vol">19</span>:261–3.</span> [<a href="/pubmed/19285864" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19285864</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.okere.2013.e12">Okere A, Reddy SS, Gupta S, Shinnar M. A cardiomyopathy in a patient with limb girdle muscular dystrophy type 2A. <span><span class="ref-journal">Circ Heart Fail. </span>2013;<span class="ref-vol">6</span>:e12–3.</span> [<a href="/pubmed/23322878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23322878</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.ono.2010.22986">Ono Y, Ojima K, Torii F, Takaya E, Doi N, Nakagawa K, Hata S, Abe K, Sorimachi H. Skeletal muscle-specific calpain is an intracellular Na+-dependent protease. <span><span class="ref-journal">J Biol Chem. </span>2010;<span class="ref-vol">285</span>:22986–98.</span> [<a href="/pmc/articles/PMC2906292/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2906292</span></a>] [<a href="/pubmed/20460380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20460380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.ono.1998.17073">Ono Y, Shimada H, Sorimachi H, Richard I, Saido TC, Beckmann JS, Ishiura S, Suzuki K. Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A. <span><span class="ref-journal">J Biol Chem. </span>1998;<span class="ref-vol">273</span>:17073–8.</span> [<a href="/pubmed/9642272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9642272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.oygard.2011.20">Oygard K, Haestad H, J&#x000f8;rgensen L. Physiotherapy, based on the Bobath concept, may influence the gait pattern in persons with limb-girdle muscle dystrophy: a multiple case series study. <span><span class="ref-journal">Physiother Res Int. </span>2011;<span class="ref-vol">16</span>:20–31.</span> [<a href="/pubmed/21110410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21110410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.pantojamelendez.2017.e0170280">Pantoja-Melendez CA, Miranda-Duarte A, Roque-Ramirez B, Zenteno JC. Epidemiological and molecular characterization of a Mexican population isolate with high prevalence of limb-girdle muscular dystrophy type 2A due to a novel Calpain-3 mutation. <span><span class="ref-journal">PLoS One. </span>2017;<span class="ref-vol">12</span>(1):e0170280.</span> [<a href="/pmc/articles/PMC5245889/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5245889</span></a>] [<a href="/pubmed/28103310" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28103310</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.pastorello.2012.230">Pastorello E, Cao M, Trevisan CP. Atypical onset in a series of 122 cases with facioscapulohumeral muscular dystrophy. <span><span class="ref-journal">Clin Neurol Neurosurg. </span>2012;<span class="ref-vol">114</span>:230–4.</span> [<a href="/pmc/articles/PMC3314982/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3314982</span></a>] [<a href="/pubmed/22079131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22079131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.pathak.2010.549">Pathak P, Sharma MC, Sarkar C, Jha P, Suri V, Mohd H, Singh S, Bhatia R, Gulati S. Limb girdle muscular dystrophy type 2A in India: a study based on semi-quantitative protein analysis, with clinical and histopathological correlation. <span><span class="ref-journal">Neurol India. </span>2010;<span class="ref-vol">58</span>:549–54.</span> [<a href="/pubmed/20739790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20739790</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.p_nissonbesnier.1998.1078">P&#x000e9;nisson-Besnier I, Richard I, Dubas F, Beckmann JS, Fardeau M. Pseudometabolic expression and phenotypic variability of calpain deficiency in two siblings. <span><span class="ref-journal">Muscle Nerve. </span>1998;<span class="ref-vol">21</span>:1078–80.</span> [<a href="/pubmed/9655129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9655129</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.perez.2010.502">Perez F, Vital A, Martin-Negrier ML, Ferrer X, Sole G. Diagnostic procedure of limb girdle muscular dystrophies 2A or calpainopathies: French cohort from a neuromuscular center (Bordeaux). <span><span class="ref-journal">Rev Neurol. </span>2010;<span class="ref-vol">166</span>:502–8.</span> [<a href="/pubmed/20044116" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20044116</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.piluso.2011.1584">Piluso G, Dionisi M, Del Vecchio Blanco F, Torella A, Aurino S, Savarese M, Giugliano T, Bertini E, Terracciano A, Vainzof M, Criscuolo C, Politano L, Casali C, Santorelli FM, Nigro V. Motor chip: a comparative genomic hybridization microarray for copy-number mutations in 245 neuromuscular disorders. <span><span class="ref-journal">Clin Chem. </span>2011;<span class="ref-vol">57</span>:1584–96.</span> [<a href="/pubmed/21896784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21896784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.piluso.2005.686">Piluso G, Politano L, Aurino S, Fanin M, Ricci E, Ventriglia VM, Belsito A, Totaro A, Saccone V, Topalo&#x0011f;lu H, Nascimbeni AC, Fulizio L, Broccolini A, Canki-Klain N, Comi LI, Nigro G, Angelini C, Nigro V. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:686–93.</span> [<a href="/pmc/articles/PMC1736133/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1736133</span></a>] [<a href="/pubmed/16141003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16141003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.pogoda.2000.295">Pogoda TV, Krakhmaleva IN, Lipatova NA, Shakhovskaya NI, Shishkin SS, Limborska SA. High incidence of 550delA mutation of CAPN3 in LGMD2 patients from Russia. <span><span class="ref-journal">Hum Mutat. </span>2000;<span class="ref-vol">15</span>:295.</span> [<a href="/pubmed/10679950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10679950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.pollitt.2001.287">Pollitt C, Anderson LV, Pogue R, Davison K, Pyle A, Bushby KM. The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach. <span><span class="ref-journal">Neuromusc Disord. </span>2001;<span class="ref-vol">11</span>:287–96.</span> [<a href="/pubmed/11297944" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11297944</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.prahm.2017.358">Prahm KP, Feldt-Rasmussen U, Vissing J. Human growth hormone stabilizes walking and improves strength in a patient with dominantly inherited calpainopathy. <span><span class="ref-journal">Neuromusc Disord. </span>2017;<span class="ref-vol">27</span>:358–62.</span> [<a href="/pubmed/28190647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28190647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.quick.2015.661">Quick S, Schaefer J, Waessnig N, Schultheiss T, Reuner U, Schoen S, Reichmann H, Strasser R, Speiser U. Evaluation of heart involvement in calpainopathy (LGMD2A) using cardiovascular magnetic resonance. <span><span class="ref-journal">Muscle Nerve. </span>2015;<span class="ref-vol">52</span>:661–3.</span> [<a href="/pubmed/26032656" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26032656</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.rajakumar.2013.2009">Rajakumar D, Alexander M, Oommen A. Oxidative stress, NF-kB and the ubiquitin proteasomal pathway in the pathology of calpainopathy. <span><span class="ref-journal">Neurochem Res. </span>2013;<span class="ref-vol">38</span>:2009–18.</span> [<a href="/pubmed/23846623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23846623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.reddy.2017.243">Reddy HM, Cho KA, Lek M, Estrella E, Valkanas E, Jones MD, Mitsuhashi S, Darras BT, Amato AA, Lidov HGW, Brownstein CA, Margulies DM, Yu TW, Salih MA, Kunkel LM, MacArthur DG, Kang PB. The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States. <span><span class="ref-journal">J Hum Genet. </span>2017;<span class="ref-vol">62</span>:243–52.</span> [<a href="/pmc/articles/PMC5266644/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5266644</span></a>] [<a href="/pubmed/27708273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27708273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.restagno.1996.173">Restagno G, Romero N, Richard I, Beckmann JS, Pagliano AM, Ferrone M, Carbonara A, Merlini L. Prenatal diagnosis of limb girdle muscular dystrophy type 2A. <span><span class="ref-journal">Neuromusc Disord. </span>1996;<span class="ref-vol">6</span>:173–6.</span> [<a href="/pubmed/8784805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8784805</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.richard.1995.259">Richard I, Beckmann JS. How neutral are synonymous codon mutations? <span><span class="ref-journal">Nat Genet. </span>1995;<span class="ref-vol">10</span>:259.</span> [<a href="/pubmed/7670461" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7670461</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.richard.1997.1128">Richard I, Brenguier L, Din&#x000e7;er P, Roudaut C, Bady B, Burgunder JM, Chemaly R, Garcia CA, Halaby G, Jackson CE, Kurnit DM, Lefranc G, Legum C, Loiselet J, Merlini L, Nivelon-Chevallier A, Ollagnon-Roman E, Restagno G, Topalo&#x0011f;lu H, Beckmann JS. Multiple independent molecular etiology for limb-girdle muscular dystrophy type 2A patients from various geographical origins. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">60</span>:1128–38.</span> [<a href="/pmc/articles/PMC1712426/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1712426</span></a>] [<a href="/pubmed/9150160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9150160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.richard.1995.27">Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, Brenguier L, Devaud C, Pasturaud P, Roudaut C, Hillaire D, Passos-Bueno MR, Zatz M, Tischfield JA, Fardeau M, Jackson CE, Cohen D, Beckmann JS. Mutations in the proteolytic enzyme calpain-3 cause limb girdle muscular dystrophy type 2A. <span><span class="ref-journal">Cell. </span>1995;<span class="ref-vol">81</span>:27–40.</span> [<a href="/pubmed/7720071" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7720071</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.richard.1999.1524">Richard I, Roudaut C, S&#x000e1;enz A, Pogue R, Grimbergen JE, Anderson LV, Beley C, Cobo AM, de Diego C, Eymard B, Gallano P, Ginjaar HB, Lasa A, Pollitt C, Topalo&#x0011f;lu H, Urtizberea JA, de Visser M, van der Kooi A, Bushby K, Bakker E, Lopez de Munain A, Fardeau M, Beckmann JS. Calpainopathy-a survey of mutations and polymorphisms. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">64</span>:1524–40.</span> [<a href="/pmc/articles/PMC1377896/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377896</span></a>] [<a href="/pubmed/10330340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10330340</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.richard.2016.248">Richard I, Hogrel JY, Stockholm D, Payan CAM, Fougerousse F, Eymard B, Mignard C, Lopez de Munain A, Fardeau M, Urtizberea A. Natural history of LGMD2A for delineating outcome measures in clinical trials. <span><span class="ref-journal">Ann Clin Transl Neurol. </span>2016;<span class="ref-vol">3</span>:248–65.</span> [<a href="/pmc/articles/PMC4818744/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4818744</span></a>] [<a href="/pubmed/27081656" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27081656</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.rosales.2013.731">Rosales XQ, Malik V, Sneh A, Chen L, Lewis S, Kota J, Gastier-Foster JM, Astbury C, Pyatt R, Reshmi S, Rodino-Klapac LR, Clark KR, Mendell JR, Sahenk Z. Impaired regeneration in LGMD2A supported by increased PAX7-positive satellite cell content and muscle-specific microRNA dysregulation. <span><span class="ref-journal">Muscle Nerve. </span>2013;<span class="ref-vol">47</span>:731–9.</span> [<a href="/pmc/articles/PMC3634894/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3634894</span></a>] [<a href="/pubmed/23553538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23553538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.sacconi.2012.41">Sacconi S, Camano P, de Greef JC, Lemmers RJ, Salviati L, Boileau P, Lopez de Munain A, van der Maarel SM, Desnuelle C. Patients with a phenotype consistent with facio scapulo humeral muscular dystrophy display genetic and epigenetic heterogeneity. <span><span class="ref-journal">J Med Genet. </span>2012;<span class="ref-vol">49</span>:41–6.</span> [<a href="/pmc/articles/PMC3560331/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3560331</span></a>] [<a href="/pubmed/21984748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21984748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.s_enz.2008.e3750">S&#x000e1;enz A, Azpitarte M, Armananzas R, Leturcq F, Alzualde A, Inza I, Garc&#x000ed;a-Bragado F, De la Herran G, Corcuera J, Cabello A, Navarro C, De La Torre C, Gallardo E, Illa I, L&#x000f3;pez de Munain A. Gene expression profiling in limb girdle muscular dystrophy 2A. <span><span class="ref-journal">PLoS One. </span>2008;<span class="ref-vol">3</span>:e3750.</span> [<a href="/pmc/articles/PMC2582180/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2582180</span></a>] [<a href="/pubmed/19015733" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19015733</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.s_enz.2005.732">S&#x000e1;enz A, Leturcq F, Cobo AM, Poza JJ, Ferrer X, Otaegui D, Camano P, Urtasun M, Vilchez J, Gutierrez-Rivas E, Emparanza J, Merlini L, Paisan C, Goicoechea M, Bl&#x000e1;zquez L, Eymard B, Lochmuller H, Walter M, Bonnemann C, Figarella-Branger D, Kaplan JC, Urtizberea JA, Marti-Masso JF, Lopez de Munain A. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. <span><span class="ref-journal">Brain. </span>2005;<span class="ref-vol">128</span>:732–42.</span> [<a href="/pubmed/15689361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15689361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.s_enz.2017.e7">S&#x000e1;enz A, L&#x000f3;pez de Munain A. Dominant LGMD2A: alternative diagnosis or hidden digenism? <span><span class="ref-journal">Brain. </span>2017;<span class="ref-vol">140</span>:e7.</span> [<a href="/pubmed/27818383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27818383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.salem.2012.92">Salem IH, Hsairi I, Mezghani N, Kenoun H, Triki C, Fakhfakh F. CAPN3 mRNA processing alterations caused by splicing mutation associated with novel genomic rearrangement of Alu elements. <span><span class="ref-journal">J Hum Genet. </span>2012;<span class="ref-vol">57</span>:92–100.</span> [<a href="/pubmed/22158424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22158424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.savarese.2016.71">Savarese M, Di Fruscio G, Torella A, Fiorillo C, Magri F, Fanin M, Ruggiero L, Ricci G, Astrea G, Passamano L, Ruggieri A, Ronchi D, Tasca G, D'Amico A, Janssens S, Farina O, Mutarelli M, Marwah VS, Garofalo A, Giugliano T, Sanpaolo S, Del Vecchio Blanco F, Esposito G, Piluso G, D'Ambrosio P, Petillo R, Musumeci O, Rodolico C, Messina S, Evil&#x000e4; A, Hackman P, Filosto M, Di Iorio G, Siciliano G, Mora M, Maggi L, Minetti C, Sacconi S, Santoro L, Claes K, Vercelli L, Mongini T, Ricci E, Gualandi F, Tupler R, De Bleecker J, Udd B, Toscano A, Moggio M, Pegoraro E, Bertini E, Mercuri E, Angelini C, Santorelli FM, Politano L, Bruno C, Comi GP, Nigro V. The genetic basis of undiagnosed muscular dystrophies and myopathies. <span><span class="ref-journal">Neurology. </span>2016;<span class="ref-vol">87</span>:71–6.</span> [<a href="/pmc/articles/PMC4932234/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4932234</span></a>] [<a href="/pubmed/27281536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27281536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.schessl.2008.54">Schessl J, Walter MC, Schreiber G, Schara U, M&#x000fc;ller CR, Lochm&#x000fc;ller H, B&#x000f6;nnemann CG, Korinthenberg R, Kirschner J. Phenotypic variability in siblings with calpainopathy (LGMD2A). <span><span class="ref-journal">Acta Myol. </span>2008;<span class="ref-vol">27</span>:54–8.</span> [<a href="/pmc/articles/PMC2858935/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2858935</span></a>] [<a href="/pubmed/19364062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19364062</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.seong.2016.484">Seong MW, Cho A, Park HW, Seo SH, Lim BC, Seol D, Cho SI, Park SS, Chae JH. Clinical application of next-generation sequencing-based gene panel in patients with muscular dystrophy: Korean experience. <span><span class="ref-journal">Clin Genet. </span>2016;<span class="ref-vol">89</span>:484–8.</span> [<a href="/pubmed/26060040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26060040</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.shaboodien.2015.152">Shaboodien G, Watkins DA, Pillay K, Beighton P, Heckmann JM, Mayosi BM. Limb girdle weakness in a marfanoid man: distinguishing calpainopathy from Becker&#x02019;s muscular dystrophy. <span><span class="ref-journal">Pract Neurol. </span>2015;<span class="ref-vol">15</span>:152–4.</span> [<a href="/pubmed/25573340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25573340</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.shin.2007.463">Shin JH, Kim HS, Lee CH, Kim CM, Park KH, Kim DS. Mutations of CAPN3 in Korean patients with limb girdle muscular dystrophy. <span><span class="ref-journal">J Korean Med Sci. </span>2007;<span class="ref-vol">22</span>:463–9.</span> [<a href="/pmc/articles/PMC2693639/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2693639</span></a>] [<a href="/pubmed/17596655" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17596655</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.simeoni.2015.292">Simeoni S, Russo V, Gigli GL, Scalise A. Facioscapulohumeral muscular dystrophy and limb-girdle muscular dystrophy: "Double trouble" overlapping syndrome? <span><span class="ref-journal">J Neurol Sci. </span>2015;<span class="ref-vol">348</span>:292–3.</span> [<a href="/pubmed/25528007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25528007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.sorimachi.2001.653">Sorimachi H, Suzuki K. The structure of calpain. <span><span class="ref-journal">J Biochem. </span>2001;<span class="ref-vol">129</span>:653–64.</span> [<a href="/pubmed/11328585" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11328585</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.stehl_kov_.2014.154">Stehl&#x000ed;kov&#x000e1; K, Sk&#x000e1;lov&#x000e1; D, Z&#x000ed;dkov&#x000e1; J, Mr&#x000e1;zov&#x000e1; L, Vondr&#x000e1;&#x0010d;ek P, Mazanec R, Voh&#x000e1;&#x00148;ka S, Haberlov&#x000e1; J, Hermanov&#x000e1; M, Z&#x000e1;me&#x0010d;n&#x000ed;k J, Sou&#x0010d;ek O, O&#x00161;lej&#x00161;kov&#x000e1; H, Dvo&#x00159;&#x000e1;&#x0010d;kov&#x000e1; N, Sola&#x00159;ov&#x000e1; P, Fajkusov&#x000e1; L. Autosomal recessive limb girdle muscular dystrophies in the Czech Republic. <span><span class="ref-journal">BMC Neurology. </span>2014;<span class="ref-vol">14</span>:154–62.</span> [<a href="/pmc/articles/PMC4145250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4145250</span></a>] [<a href="/pubmed/25135358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25135358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.stramare.2010.585">Stramare R, Beltrame V, Dal Borgo R, Gallimberti L, Frigo AC, Pegoraro E, Angelini C, Rubaltelli L, Feltrin GP. MRI in the assessment of muscular pathology: a comparison between limb-girdle muscular dystrophies, hyaline body myopathies and myotonic dystrophies. <span><span class="ref-journal">Radiol Med. </span>2010;<span class="ref-vol">115</span>:585–99.</span> [<a href="/pubmed/20177980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20177980</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.straub.2012.s42">Straub V, Carlier PG, Mercuri E. TREAT-NMD workshop: pattern recognition in genetic muscle diseases using muscle MRI. <span><span class="ref-journal">Neuromusc Disord. </span>2012;<span class="ref-vol">22</span>:S42–53.</span> [<a href="/pubmed/22980768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22980768</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.sveen.2013.163">Sveen ML, Andersen SP, Ingelsrud LH, Blichter S, Olsen NE, Jonck S, Krag TO, Vissing J. Resistance training in patients with limb girdle and Becker muscular dystrophies. <span><span class="ref-journal">Muscle Nerve. </span>2013;<span class="ref-vol">47</span>:163–9.</span> [<a href="/pubmed/23169433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23169433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.talim.2001.692">Talim B, Ognibene A, Mattioli E, Richard I, Anderson LV, Merlini L. Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:692–3.</span> [<a href="/pubmed/11245732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11245732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.ten_dam.2012.1716">ten Dam L, van der Kooi AJ, Van Wattingen M, De Haan RJ, De Visser M. Reliability and accuracy of skeletal muscle imaging in limb girdle muscular dystrophies. <span><span class="ref-journal">Neurology. </span>2012;<span class="ref-vol">79</span>:1716–23.</span> [<a href="/pubmed/23035061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23035061</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.thompson.2016.294">Thompson R, Straub V. Limb girdle muscular dystrophies - international collaborations for translational research. <span><span class="ref-journal">Nat Rev Neurol. </span>2016;<span class="ref-vol">12</span>:294–309.</span> [<a href="/pubmed/27033376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27033376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.todorova.2007.225">Todorova A, Georgieva B, Tournev I, Todorov T, Bogdanova N, Mitev V, Mueller CR, Kremensky I, Horst J. A large deletion and novel point mutations in the calpain 3 gene (CAPN3) in Bulgarian LGMD2A patients. <span><span class="ref-journal">Neurogenetics. </span>2007;<span class="ref-vol">8</span>:225–9.</span> [<a href="/pubmed/17318636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17318636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.topalo_lu.1997.212">Topalo&#x0011f;lu H, Din&#x000e7;er P, Richard I, Ak&#x000e7;&#x000f6;ren Z, Alehan D, Ozme S, Ca&#x0011f;lar M, Karaduman A, Urtizberea JA, Beckmann JS. Calpain-3 deficiency causes a mild muscular dystrophy in childhood. <span><span class="ref-journal">Neuropediatrics. </span>1997;<span class="ref-vol">28</span>:212–6.</span> [<a href="/pubmed/9309711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9309711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.urtasun.1998.1735">Urtasun M, S&#x000e1;enz A, Roudaut C, Poza JJ, Urtizberea JA, Cobo AM, Richard I, Garcia Bragado F, Leturcq F, Kaplan JC, Marti Masso JF, Beckmann JS, Lopez de Munain A. Limb-girdle muscular dystrophy in Guipuzcoa (Basque Country, Spain). <span><span class="ref-journal">Brain. </span>1998;<span class="ref-vol">121</span>:1735–47.</span> [<a href="/pubmed/9762961" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9762961</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.vainzof.2003.624">Vainzof M, de Paula F, Tsanaclis AM, Zatz M. The effect of calpain 3 deficiency on the pattern of muscle degeneration in the earliest stages of LGMD2A. <span><span class="ref-journal">J Clin Pathol. </span>2003;<span class="ref-vol">56</span>:624–6.</span> [<a href="/pmc/articles/PMC1770017/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1770017</span></a>] [<a href="/pubmed/12890817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12890817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.van_der_kooi.1996.1471">van der Kooi AJ, Barth PG, Busch HF, de Haan R, Ginjaar HB, van Essen AJ, van Hooff LJ, H&#x000f6;weler CJ, Jennekens FG, Jongen P, Oosterhuis HJ, Padberg GW, Spaans F, Wintzen AR, Wokke JH, Bakker E, van Ommen GJ, Bolhuis PA, de Visser M. The clinical spectrum of limb girdle muscular dystrophy. A survey in The Netherlands. <span><span class="ref-journal">Brain. </span>1996;<span class="ref-vol">119</span>:1471–80.</span> [<a href="/pubmed/8931572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8931572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.van_der_kooi.2007.2125">van der Kooi AJ, Frankhuizen WS, Barth PG, Howeler CJ, Padberg GW, Spaans F, Wintzen AR, Wokke JH, van Ommen GJ, de Visser M, Bakker E, Ginjaar HB. Limb-girdle muscular dystrophy in the Netherlands: gene defect identified in half the families. <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">68</span>:2125–8.</span> [<a href="/pubmed/17562833" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17562833</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.vissing.2016.2154">Vissing J, Barresi R, Witting N, Van Ghelue M, Gammelgaard L, Bindoff LA, Straub V, Lochm&#x000fc;ller H, Hudson J, Wahl CM, Arnardottir S, Dahlbom K, Jonsrud C, Duno M. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. <span><span class="ref-journal">Brain. </span>2016;<span class="ref-vol">139</span>:2154–63.</span> [<a href="/pubmed/27259757" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27259757</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.wattjes.2010.2447">Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. <span><span class="ref-journal">Eur Radiol. </span>2010;<span class="ref-vol">20</span>:2447–60.</span> [<a href="/pmc/articles/PMC2940021/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2940021</span></a>] [<a href="/pubmed/20422195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20422195</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.young.1992.1370">Young K, Foroud T, Williams P, Jackson CE, Beckmann JS, Cohen D, Conneally PM, Tischfield J, Hodes ME. Confirmation of linkage of limb-girdle muscular dystrophy, type 2, to chromosome 15. <span><span class="ref-journal">Genomics. </span>1992;<span class="ref-vol">13</span>:1370–1.</span> [<a href="/pubmed/1505977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1505977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.zatz.2003.532">Zatz M, de Paula F, Starling A, Vainzof M. The 10 autosomal recessive limb-girdle muscular dystrophies. <span><span class="ref-journal">Neuromusc Disord. </span>2003;<span class="ref-vol">13</span>:532–44.</span> [<a href="/pubmed/12921790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12921790</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.zatz.2000.511">Zatz M, Vainzof M, Passos-Bueno MR. Limb-girdle muscular dystrophy: one gene with different phenotypes, one phenotype with different genes. <span><span class="ref-journal">Curr Opin Neurol. </span>2000;<span class="ref-vol">13</span>:511–7.</span> [<a href="/pubmed/11073356" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11073356</span></a>]</div></li></ul></div><div id="lgmd2a.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="lgmd2a.REF.kang">Kang PB, Kunkel LM. The muscular dystrophies. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G., eds. <em>The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</em> Chap 216. New York, NY: McGraw-Hill.</div></li></ul></div></div><div id="lgmd2a.Chapter_Notes"><h2 id="_lgmd2a_Chapter_Notes_">Chapter Notes</h2><div id="lgmd2a.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>3 August 2017 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 July 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 July 2010 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically</div></li><li class="half_rhythm"><div>3 December 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 December 2005 (ca) Revision: <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> available</div></li><li class="half_rhythm"><div>10 May 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>29 November 2004 (ca) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1313</span><span class="label">PMID: <a href="/pubmed/20301490" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301490</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/caffey/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/campo-dysp/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1313&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1313/?report=reader">PubReader</a></li><li><a href="/books/NBK1313/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1313" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1313" style="display:none" title="Cite this Page"><div class="bk_tt">Angelini C, Fanin M. Calpainopathy. 2005 May 10 [Updated 2017 Aug 3]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1313/pdf/Bookshelf_NBK1313.pdf">PDF version of this page</a> (568K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#lgmd2a.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#lgmd2a.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#lgmd2a.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#lgmd2a.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#lgmd2a.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#lgmd2a.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#lgmd2a.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#lgmd2a.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#lgmd2a.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#lgmd2a.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#lgmd2a.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#lgmd2a.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=825[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CAPN3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1313+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1497740" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1497740" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1497740" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1497740" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301609" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emery-Dreifuss Muscular Dystrophy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emery-Dreifuss Muscular Dystrophy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bonne G, Leturcq F, Ben Yaou R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301559" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Caveolinopathies</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Caveolinopathies<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bruno C, Sotgia F, Gazzerro E, Minetti C, Lisanti MP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301676" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Collagen Type VI-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Collagen Type VI-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lampe AK, Flanigan KM, Bushby KM, Hicks D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22675738" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">LAMA2</i>-Related Muscular Dystrophy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">LAMA2</i>-Related Muscular Dystrophy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Quijano-Roy S, Sparks SE, Rutkowski A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301298" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Darras BT, Urion DK, Ghosh PS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301490" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301490" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e042916dde089116998efde">Calpainopathy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Calpainopathy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:29:26-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8AEE42E042835100000000005D0022&amp;ncbi_session=CE8AEE42E0429151_0093SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1313%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1313&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1313/&amp;ncbi_pagename=Calpainopathy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8AEE42E0429151_0093SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>